Introduction {#cesec10}
============

China has made enormous strides in improving health in the past few decades. Between 1970 and 2010, male life expectancy increased from 60·4 years to 72·9 years and female life expectancy increased from 63·5 years to 79·0 years;[@bib1] the under-5 mortality rate reduced from 100·6 per 1000 to 12·9 per 1000;[@bib1] and the total fertility rate declined from 4·77 to 1·64 children per woman.[@bib2] Rapidly increasing income per head, an ageing population, and longer lifespans have led to a rapid change in the health profile of the nation. Some counties within the country, however, remain relatively poor and continue to have a set of health challenges dominated by communicable, maternal, and neonatal causes.[@bib3], [@bib4] China needs to understand and formulate a long-range strategy to tackle several challenges in public health and medical care at the same time.

Before health-care reform was announced in 2009,[@bib5] the Chinese Government was faced with widespread public discontent stemming from unaffordable access to health care and growing inequalities in access to health care and health status across regions and populations.[@bib6], [@bib7], [@bib8], [@bib9] Health improvement fell short of what China\'s rapid economic growth should have afforded.[@bib10] Some previously eliminated infectious diseases re-emerged[@bib11] and incidence of some non-communicable diseases increased.[@bib12], [@bib13] The 2002--03 severe acute respiratory syndrome (SARS) outbreak was a wake-up call exposing the inadequacies of the public health protection and surveillance system, and emphasising the important role for government in guidance of the evolution of health in China. Health system reforms focused on delivering improved access to quality clinical care[@bib14] are now underway but can be better informed by a broad assessment of China\'s progress in health.

Several data systems provide substantial detail about levels and trends in health in China, including various national surveys of health, civil registration, medical certification of causes of death in some cities and counties,[@bib15] the Disease Surveillance Points system,[@bib16] a sophisticated infectious disease surveillance network,[@bib17] population-based cancer registries,[@bib18] a maternal and child surveillance system,[@bib17] and demographic surveys[@bib19], [@bib20] and censuses.[@bib21], [@bib22] Despite these data systems, a comprehensive and comparable assessment of health challenges and how they change over time is not available. Opportunities to compare China\'s health performance with other countries to learn where China has done well and where scope for improvement exists have thus been limited.

In this report, we use the results of the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) to examine in detail the transformation of health in China from 1990 to 2010 and to benchmark health challenges in China to 18 major high-income and rapidly developing countries that are members of the G20.

Methods {#cesec20}
=======

Overview {#cesec30}
--------

Detail on the data, approaches to enhancing data quality and comparability, and statistical modelling and metrics for the GBD 2010 have been reported elsewhere.[@bib1], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29] In brief, GBD 2010 lists 291 diseases and injuries, organised in a hierarchy. For each of these causes, up to 24 sequelae exist that are clinical outcomes related to specific diseases and injuries, such as neuropathy due to diabetes. The study included 1160 sequelae.

The 2010 GBD study used numerous metrics to report results on health loss related to specific causes of disease and injury: deaths and death rates, years of life lost due to premature mortality (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs). YLLs are computed by multiplying the number of deaths in each age group by a reference life expectancy at that age. The life expectancy at birth in the reference life table is 86·0 years based on the lowest reported death rates for each age group across countries in 2010, and is intended to represent an achievable pattern of mortality.[@bib26] Years lived with disability are calculated from the prevalence of a sequela multiplied by the disability weight for that sequela. Disability weights are based on surveys of the general population.[@bib27] DALYs are the sum of YLLs and YLDs. The GBD uses another indicator, healthy life expectancy (HALE), to summarise overall population health in one number, accounting for both length of life and levels of ill health at different ages.[@bib28]

Mortality {#cesec40}
---------

Wang and colleagues[@bib1] provide a detailed description on how rates of age-specific mortality have been estimated for each sex, country, and year. [Appendix p 1](#sec1){ref-type="sec"} provides details on each of the sources available for measurement of the under-5 mortality rate, and [appendix pp 2--3](#sec1){ref-type="sec"} provides similar information on measuring the probability of death between ages 15 years and 60 years. Available national data sources on the age pattern of mortality provide similar distributions of deaths for individuals aged 15--79 years ([appendix pp 4--5](#sec1){ref-type="sec"}).

Causes of death {#cesec50}
---------------

We calculated numbers of deaths and YLLs based on underlying cause of death estimates for 235 of 291 causes of mortality, and for 20 age groups, both sexes, and 187 countries.[@bib24] The [appendix p 11](#sec1){ref-type="sec"} provides a listing of the major sources of information used to assess causes of death in China since 1980, including population-based cancer registry data. We assessed the quality of each data source, and mapped the codes for various Chinese variants of the International Classification of Diseases and Injuries (ICD) tabulation lists to the GBD 2010 cause list. We reassigned deaths assigned to ill-defined diagnoses or to disorders that are not likely to be underlying causes of death with standard algorithms.[@bib30], [@bib31] GBD 2010 provides the most comprehensive effort to date to enhance the comparability of cause of death data across countries because it adjusts for revisions of the ICD and the redistribution of garbage codes. Garbage codes are causes of death that should not be identified as underlying causes of death but have been entered as the underlying cause of death on death certificates. Classic examples of garbage codes include senility or cardiopulmonary arrest. Uncertainty in cause of death estimates has been captured with standard simulation methods by taking 1000 draws[@bib32] for each age, sex, country, year, and cause.[@bib24] Final uncertainty for death numbers and YLLs also reflects uncertainty in the levels of all-cause mortality in each age-sex-country-year.

YLDS and HALE {#cesec60}
-------------

We undertook prevalence estimation for each sequela with a systematic analysis of published and available unpublished data sources for prevalence, incidence, remission, and excess mortality. For most sequelae, we made estimates on the basis of a database for all age-sex-country-year groups, with a Bayesian meta-regression technique developed for the GBD 2010 (DisMod-MR). Several data sources have been used for the estimates of YLDs in China, including published studies,[@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38] multiple national surveys,[@bib39], [@bib40] a set of 46 cancer registries,[@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46] and the Centers for Disease Control and Prevention (CDC) surveillance system.[@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53] The effects of treatment depending on the cause are captured through changes in prevalence, changes in the severity distribution across sequelae (eg, for chronic obstructive pulmonary disease), and for some injuries different disability weights for treated and untreated outcomes. Access to treatment for injuries is estimated on the basis of an indicator of access to health systems.[@bib29]

For GBD 2010, disability weights were measured for 220 unique health states that cover the 1160 disease and injury sequelae.[@bib27] Disability weights were generated from more than 30 000 respondents collected through population-based surveys in five countries---USA, Peru, Tanzania, Bangladesh, and Indonesia---and an open internet survey. 271 respondents of the internet survey were from China. Uncertainty in the disability weight for each sequela has been propagated into the estimates of YLDs for each disease and injury. We combined information about age-specific mortality rates, and about overall age-specific YLDs per person into the overall measure of health expectancy, HALE, using a standard approach to extending the life table to capture adjustments for non-fatal health outcomes.[@bib28]

Risk factors {#cesec70}
------------

Deaths, YLLs, YLDs, and DALYs attributable to 67 risk factors or clusters of risk factors were assessed with three key inputs.[@bib23] First, for each risk--outcome pair, relative risks of mortality or morbidity, or both, were estimated on the basis of meta-analyses of the published literature. Second, each risk factor exposure distribution in each country, age, and sex group was estimated on the basis of published and unpublished data sources with mostly Bayesian estimation methods.[@bib23] For China, key sources included the 2002 China National Nutrition and Health Survey, the China Global Youth Tobacco Survey, the Second National Health Services Survey, the 1996 Global Youth Tobacco Survey, the 1996 National Prevalence Survey, the After-MONICA, the INTERSALT Beijing, the INTERMAP Beijing, and the 2000 and 2005 national censuses. Third, we estimated attributable deaths or DALYs by comparing the present distribution of exposure to a theoretical minimum risk counterfactual distribution of exposure selected for each risk factor. Each risk factor or cluster of risk factors was analysed separately and therefore the sum of attributable fractions for a disease or injury can be greater than 100%. Uncertainty in the relative risks, exposure estimates, and theoretical minimum risk distributions and uncertainty in the background outcome rates have been propagated into the final estimates.

Benchmarking {#cesec80}
------------

For outcomes measured for specific age groups (deaths, YLLs, YLDs, and DALYs), we directly computed age-standardised rates with the WHO age-standard.[@bib54] This standard is very close to the distribution of China\'s population in 2010. For each disease, injury, or risk factor, we ranked countries in 1990 and 2010 by the age-standardised rates for each outcome measure. We compared China outcomes to the 18 other countries that are members of the G20 (the 20th member is the European Union). The G20 is the set of developed and developing countries identified as global agenda setters. Comparisons of China with this group provide insights into China\'s standing relative to this set of developed or rapidly developing countries. For each quantity of interest in the GBD, 1000 draws were taken from the posterior distribution. We computed ranks across causes and percentage change from 1990 to 2010 at the draw level. We report 95% uncertainty intervals for ranks. For percentage change from 1990 to 2010 computed at the level of each draw, we report the median percentage change, which is less sensitive to extreme values than the mean percentage change. For a specific country and cause, we tested whether a country was significantly greater than the G20 mean, indistinguishable from the mean, or below the mean.

Role of the funding source {#cesec90}
--------------------------

The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility to submit for publication.

Results {#cesec100}
=======

[Table 1](#tbl1){ref-type="table"} provides an overall comparative view of health across the G20. Between 1990 and 2010, China had a 6·4 year improvement in life expectancy at birth for both sexes combined (from 69·3 years to 75·7 years), rising one rank past Mexico in a league table of G20 countries. In terms of the age-standardised death rate, China ranked 13th (95% uncertainty interval \[UI\] 11th to 14th) in 2010, ahead of Turkey, Brazil, Indonesia, Russia, India, and South Africa, but behind countries such as South Korea, USA, Saudi Arabia, Argentina, and Mexico. Across the G20, age-standardised YLL rate varied by more than sevenfold. China had the lowest levels of age-standardised YLDs in 2010 across the G20; although Japan, South Korea, and Mexico had rates that were statistically indistinguishable from China. Across G20 countries the ratio of the highest to lowest age-standardised YLD rate was only 1·6. China ranks at 10th (8th to 10th) for HALE in 2010, only 0·4 years (95% UI −0·4 to 1·2) behind the USA. Japan had a healthy life expectancy in 2010 that was 5·2 years (4·3--6·2) longer than that reported for China.Table 1Age-standardised death rates, YLLs, and YLDs, and life expectancy at birth and HALE at birth for 1990 and 2010 for both sexes combined for 19 members countries of the G20**Age-standardised death rate (per 100 000)Age-standardised YLLs (per 100 000)Age-standardised YLDs (per 100 000)Life expectancy at birth (years)HALE at birth (years)1990201019902010199020101990201019902010**RateRankRateRankRateRankRateRankRateRankRateRankLERankLERankHALERankHALERankChina896 (859--944)14 (14--15)607 (581--633)13 (11--14)24 989 (23 792--26 293)13 (13--14)14 024 (13 416--14 996)11 (11--12)9639 (7954--11 700)2(1--4)8782 (7291--10 497)1(1--2)69·3 (68·3--70·3)13 (13--15)75·7 (74·9--76·5)12 (11--13)61·7 (59·9--63·3)13 (12--13)67·8 (66·1--69·3)10 (8--10)Argentina731 (725--736)10 (10--10)597 (593--602)11 (11--13)19 400 (19 003--19 767)11 (10--11)14 343 (14 163--14 574)12 (11--12)11 154 (9280--13 517)9(5--15)10 843 (8885--13 183)7 5--15)72·5 (72·5--72·6)10 (9--11)76·0 (75·9--76·0)11 (11--12)63·1 (61·2--64·7)10 (9--12)66·1 (64·0--67·9)12 (11--13)Australia568 (564--571)5 (5--5)389 (386--393)2(2--3)12 381 (12 213--12 520)4(4--4)7722 (7610--7897)3(3--3)11 153 (9223--13 293)8 (6--13)10 979 (9088--13 165)9(6--13)76·9 (76·8--76·9)5(4--5)81·5 (81·4--81·6)2(2--3)66·6 (64·7--68·4)4(2--5)70·4 (68·2--72·3)2(2--5)Brazil854 (846--863)13 (13--13)670 (665--674)15 (15--15)26 370 (25 718--27 152)15 (14--15)17 580 (17 240--17 932)15 (14--15)12 016 (9914--14 293)14 (12--17)11 637 (9670--13 849)15 (11--17)69·1 (68·9--69·3)14 (13--14)74·1 (73·9--74·3)15 (14--15)59·6 (57·8--61·3)15 (14--15)64·0 (62·0--65·7)15 (14--15)Canada558 (554--561)3(3--3)422 (418--427)5(5--5)12 079 (11 923--12 203)2(2--2)8546 (8429--8714)5 (4--6)10 806 (8988--12 878)6 (4--10)10 845 (9035--12 854)6(5--13)77·2 (77·1--77·3)2(2--2)80·6 (80·4--80·8)5(5--5)67·1 (65·2--68·8)2(2--4)69·7 (67·8--71·6)5(4--7)Germany644 (641--646)9(8--9)433 (429--440)6(6--6)14 032 (13 863--14 171)7(7--7)8512 (8383--8739)4(4--5)11 165 (9271--13 253)10 (6--13)11 015 (9177--13 070)10 (6--13)75·4 (75·3--75·4)7(7--8)80·2 (80·1--80·4)6(6--6)65·4 (63·5--67·1)8(6--8)69·3 (67·3--71·1)7(6--8)France549 (545--553)2(2--2)408 (403--416)4(4--4)12 717 (12 535--12 858)5(5--5)8666 (8516--8912)6(5--6)11 358 (9418--13 475)11 (7--14)11 194 (9279--13 307)12 (6--15)77·1 (77·0--77·1)3(3--3)80·9 (80·7--81·1)4(4--4)66·6 (64·6--68·4)5(2--5)69·7 (67·6--71·6)6(4--7)UK638 (634--642)6(6--8)455 (452--458)8(8--8)13 452 (13 296--13 581)6(6--6)8949 (8871--9052)8(7--8)11 453 (9466--13 603)12 (8--14)11 435 (9482--13 569)14 (10--16)75·7 (75·6--75·7)6(6--7)79·9 (79·9--80·0)7(7--7)65·5 (63·6--67·3)7(6--8)68·8 (66·7--70·7)8(7--9)Indonesia1033 (1005--1062)17 (17--17)867 (831--903)16 (16--16)34 584 (33 009--36 082)18 (17--18)24 178 (23 026--25 502)16 (16--17)12 101 (9909--14 596)15 (10--18)11 107 (9122--13 402)11 (5--16)65·0 (64·5--65·5)17 (17--18)69·7 (68·5--70·9)16 (16--17)56·2 (54·4--57·8)17 (17--18)60·9 (59·0--62·7)16 (16--17)India1447 (1389--1530)19 (19--19)1097 (1011--1166)18 (18--18)50 084 (47 613--53 409)19 (19--19)33 366 (30 670--35 506)18 (18--18)13 727 (11 265--16 542)19 (18--19)12 494 (10 287--14 967)18 (16--18)58·3 (56·9--59·7)19 (19--19)65·2 (63·5--66·9)18 (18--18)49·8 (47·8--51·7)19 (19--19)56·2 (53·8--58·3)18 (18--18)Italy561 (558--563)4(4--4)389 (386--396)3(2--3)12 202 (12 053--12 330)3(3--3)7485 (7359--7703)2(2--2)11 038 (9150--13 174)7(5--12)10 907 (9081--12 895)8(5--12)77·0 (76·9--77·0)4(4--5)81·5 (81·3--81·6)3(2--3)66·8 (64·8--68·6)3(2--5)70·3 (68·3--72·2)3(2--5)Japan469 (466--471)1(1--1)352 (350--356)1(1--1)9658 (9552--9750)1(1--1)6827 (6761--6939)1(1--1)9406 (7794--11 361)1(1--3)9094 (7465--10 904)2(1--4)79·1 (79·1--79·1)1(1--1)82·6 (82·6--82·7)1(1--1)69·9 (68·0--71·5)1(1--1)73·0 (71·2--74·7)1(1--1)South Korea813 (802--822)12 (12--12)447 (441--452)7(7--7)18 830 (18 158--19 318)10 (9--10)8941 (8801--9093)7(7--8)10 074 (8289--12 073)3(2--7)9575 (7888--11 559)4(2--5)72·1 (71·6--72·6)11 (10--11)79·7 (79·6--79·8)8(8--8)63·8 (62·1--65·4)9 (9--11)70·3 (68·4--72·0)4(2--6)Mexico740 (732--749)11 (11--11)604 (599--609)12 (12--14)22 775 (22 171--23 502)12 (12--12)15 658 (15 365--15 976)13 (13--14)10 092 (8414--12 094)4(2--6)9364 (7762--11 245)3(2--4)71·5 (71·2--71·9)12 (11--12)75·5 (75·2--75·7)13 (12--14)62·9 (61·1--64·4)11 (10--12)66·9 (65·2--68·4)11 (11--12)Russia953 (947--959)16 (15--16)952 (947--959)17 (17--17)25 715 (25 268--26 205)14 (13--14)25 387 (25 067--25 797)17 (16--17)11 536 (9582--13 845)13 (7--15)11 444 (9494--13 509)13 (8--17)68·7 (68·4--69·0)15 (14--15)68·9 (68·6--69·1)17 (16--17)59·8 (58·1--61·3)14 (14--15)60·0 (58·4--61·6)17 (16--17)Saudi Arabia641 (594--703)8 (6--9)538 (517--560)10 (10--10)17 367 (15 994--19 202)9 (9--10)12 637 (12 009--13 524)10 (10--10)12 745 (10 465--15 351)17 (14--19)12 489 (10 266--15 051)17 (15--18)74·0 (72·0--75·9)9 (6--11)77·1 (76·1--78·1)10 (10--10)62·7 (60·0--65·4)12 (9--13)65·3 (62·8--67·7)13 (12--14)Turkey942 (895--980)15 (14--16)628 (584--660)14 (11--14)30 025 (28 350--31 541)16 (16--16)16 760 (15 331--18 071)14 (13--15)12 442 (10 380--14 783)16 (14--18)11 885 (9895--14 020)16 (12--17)67·1 (66·1--68·1)16 (16--16)74·4 (72·8--75·7)14 (12--15)57·7 (55·8--59·4)16 (16--16)64·0 (61·7--66·2)14 (13--15)USA639 (637--642)7(6--8)516 (513--519)9(9--9)15 130 (14 957--15 283)8(8--8)11 447 (11 312--11 630)9(9--9)10 503 (8753--12 449)5 (3--7)10 509 (8803--12 375)5(5--9)75·2 (75·2--75·2)8(8--9)78·2 (78·2--78·3)9(9--9)65·8 (64·0--67·4)6(6--8)68·1 (66·3--69·8)9(9--10)South Africa1133 (1071--1180)18 (18--18)1266 (1200--1334)19 (19--19)34 540 (32 586--36 273)17 (17--18)48 286 (45 928--51 074)19 (19--19)12 905 (10 595--15 408)18 (15--19)13 826 (11 406--16 608)19 (19--19)64·6 (63·5--65·8)18 (17--18)59·9 (57·5--61·8)19 (19--19)55·5 (53·5--57·3)18 (17--18)51·1 (48·8--53·2)19 (19--19)[^2]

Changes in age-specific mortality rates in China from 1990 to 2010 varied widely by age and sex ([figure 1](#fig1){ref-type="fig"} ). Under-5 mortality rates declined by nearly 70% (95% UI 61·3--77·9). We noted declines in female adult mortality with declines in excess of 50% for age groups 0 years to 30--34 years. Progress in reduction of male mortality was substantially worse than that noted for women. [Figure 1](#fig1){ref-type="fig"} shows comparative progress in reduction of age-specific mortality with other G20 countries. For men, China\'s relative rank in terms of age-specific mortality was lower than the G20 average at ages older than 50 years and relatively little changed between 1990 and 2010. For women and girls, however, we noted a substantial relative improvement, with ranks improving from 16th to 10th in the age groups 15--19 years through to 50--54 years. Although we noted a relative improvement for women older than 60 years, the improvement was less pronounced.Figure 1Age-specific mortality in China, 1990--2010(A) Percentage change in age-specific mortality, by sex, in China between 1990 and 2010. (B) Rank of age-specific mortality for male individuals in China compared with 18 other members of the G20. (C) Rank of age-specific mortality for female individuals in China compared with 18 other members of the G20. Shaded areas show 95% uncertainty intervals (UI). In some cases, the 95% UI has an upper and lower bound equal to the rank of the mean death rate. Countries have been ranked such that the best performer is ranked as one for each indicator.

[Table 2](#tbl2){ref-type="table"} shows the number of deaths and the age-standardised death rate for each cause in 1990 and 2010. Communicable, maternal, neonatal, and nutritional disorders have declined by 59·5% (95% UI 54·4--63·8). Among these disorders, however, the large increase in HIV deaths is notable. The number of deaths from non-communicable disease rose from 5·9 million (5·7--6·3) to 7·0 million (6·7--7·3), but age-standardised death rates declined 27·8% (24·2--33·1); this difference was caused by population growth and ageing. Rising age-standardised rates have occurred for some causes such as lung cancer, ischaemic heart disease, atrial fibrillation, peripheral vascular disease, diabetes, and road injury.Table 2Deaths (in thousands) and age-standardised death rates per 100 000 for 231 causes in 1990 and 2010 for all ages, both sexes combined, and percentage change from 1990 to 2010 in China**All ages deaths (thousands)Age-standardised death rate (per 100 000)**19902010Median %Δ19902010Median %Δ**All causes7997·5 (7663·4--8426·7)8303·7 (7939·6--8678·7)4·0895·9 (858·8--943·6)606·8 (580·7--632·7)--32·1Communicable, maternal, neonatal, and nutritional disorders1207·8 (1105·1--1303·8)490·4 (441·9--548·5)--59·5108·5 (100·3--117·4)40·7 (36·6--45·2)--62·5HIV/AIDS and tuberculosis**169·2 (140·8--200·2)80·9 (63·6--100·1)−52·218·6 (15·4--22·0)5·5 (4·3--6·8)−70·2Tuberculosis169·0 (140·5--200·0)44·7 (32·7--54·2)−73·018·5 (15·4--21·9)3·1 (2·3--3·8)−82·8HIV/AIDS0·2 (0·0--0·6)36·2 (25·1--49·2)13 860·7\<0·05 (0·0--0·1)2·4 (1·7--3·3)9447·6HIV disease resulting in mycobacterial infection\<0·05 (0·0--0·1)2·0 (1·4--2·7)6050·5\<0·05 (0·0--0·05)0·1 (0·1--0·2)4159·1HIV disease resulting in other specified or unspecified diseases0·2 (0·0--0·5)34·2 (23·9--46·7)14 809·7\<0·05 (0·0--0·1)2·3 (1·6--3·1)10 224·8**Diarrhoea, lower respiratory infections, meningitis, and other common infectious diseases**558·4 (492·7--623·3)223·2 (188·9--257·3)−59·950·6 (45·6--56·5)18·2 (15·5--21·1)−63·9Diarrhoeal diseases71·3 (61·5--83·2)4·4 (3·7--5·3)−93·96·4 (5·6--7·3)0·4 (0·3--0·5)−94·0Cholera2·0 (1·2--3·5)0·1 (0·1--0·2)−95·30·2 (0·1--0·3)\<0·05 (0·0--0·05)−94·0Other salmonella infections5·6 (4·0--7·9)0·4 (0·3--0·5)−93·60·5 (0·4--0·7)\<0·05 (0·0--0·05)−93·8Shigellosis4·8 (3·6--6·5)0·3 (0·3--0·5)−93·10·5 (0·4--0·6)\<0·05 (0·0--0·05)−93·9Enteropathogenic *E coli* infection6·6 (4·0--10·2)0·3 (0·2--0·5)−95·40·5 (0·3--0·8)\<0·05 (0·0--0·1)−94·1Enterotoxigenic *E coli* infection6·4 (4·8--8·4)0·5 (0·3--0·6)−92·90·6 (0·5--0·8)\<0·05 (0·0--0·1)−93·9Campylobacter enteritis6·7 (4·3--9·8)0·4 (0·3--0·6)−94·40·6 (0·4--0·8)\<0·05 (0·0--0·1)−94·0Amoebiasis1·8 (1·3--2·5)0·2 (0·1--0·2)−91·40·2 (0·1--0·3)\<0·05 (0·0--0·05)−93·9Cryptosporidiosis5·5 (3·4--8·4)0·3 (0·2--0·4)−95·40·4 (0·3--0·7)\<0·05 (0·0--0·05)−94·0Rotaviral enteritis17·8 (13·1--23·6)0·9 (0·6--1·2)−94·91·5 (1·1--1·9)0·1 (0·1--0·1)−94·0Other diarrhoeal diseases14·1 (9·6--20·0)1·1 (0·8--1·5)−92·21·4 (1·0--2·0)0·1 (0·1--0·1)−93·9Typhoid and paratyphoid fevers12·0 (1·4--22·6)11·9 (1·4--21·9)−1·01·0 (0·1--1·9)0·9 (0·1--1·7)−6·5Lower respiratory infections392·4 (342·3--441·9)195·2 (162·9--226·3)−50·136·4 (32·3--41·5)15·9 (13·4--18·5)−56·2Influenza75·2 (61·9--91·1)40·8 (33·4--47·9)−45·57·1 (6·0--8·6)3·3 (2·7--3·9)−53·7Pneumococcal pneumonia89·7 (74·8--107·1)60·5 (48·9--72·4)−32·39·0 (7·6--10·9)4·8 (3·9--5·8)−46·3*H influenzae* type B pneumonia102·2 (79·6--126·8)30·4 (25·5--35·8)−70·38·6 (6·8--10·5)2·6 (2·2--3·1)−69·9Respiratory syncytial virus pneumonia56·1 (39·4--74·7)7·3 (5·5--10·0)−87·24·3 (3·1--5·7)0·8 (0·5--1·1)−83·0Other lower respiratory infections69·2 (53·4--93·3)56·2 (43·0--70·0)−17·57·3 (5·7--9·6)4·5 (3·4--5·6)−38·2Upper respiratory infections0·3 (0·3--0·4)\<0·05 (0·0--0·1)−89·4\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)−84·9Otitis media1·0 (0·0--11·6)0·3 (0·0--2·9)−74·60·1 (0·0--1·0)\<0·05 (0·0--0·3)−74·1Meningitis30·6 (24·5--34·7)7·7 (6·4--10·2)−76·02·7 (2·2--3·1)0·6 (0·5--0·8)−78·3Pneumococcal meningitis5·8 (4·3--6·9)1·4 (1·1--2·0)−77·00·5 (0·4--0·6)0·1 (0·1--0·2)−79·5*H influenzae* type B meningitis4·8 (3·8--5·9)0·9 (0·7--1·2)−81·10·4 (0·3--0·5)0·1 (0·1--0·1)−78·5Meningococcal infection4·1 (3·0--4·9)1·0 (0·8--1·3)−77·70·4 (0·3--0·4)0·1 (0·1--0·1)−79·6Other meningitis15·9 (12·1--18·4)4·4 (3·6--6·0)−74·11·5 (1·1--1·7)0·3 (0·3--0·5)−78·1Encephalitis3·7 (3·0--4·4)0·7 (0·5--0·8)−82·10·3 (0·2--0·3)0·1 (0·1--0·1)−78·7Diphtheria0·2 (0·0--1·4)\<0·05 (0·0--0·4)−73·4\<0·05 (0·0--0·1)\<0·05 (0·0--0·05)−68·8Whooping cough3·3 (0·0--16·4)0·5 (0·0--2·2)−86·00·3 (0·0--1·3)\<0·05 (0·0--0·2)−80·6Tetanus19·0 (8·9--34·8)1·7 (0·5--5·2)−91·91·6 (0·7--3·1)0·1 (0·0--0·4)−91·3Measles23·7 (7·9--60·2)0·4 (0·1--1·1)−98·31·8 (0·6--4·6)\<0·05 (0·0--0·1)−97·7Varicella0·8 (0·0--5·5)0·5 (0·0--3·7)−34·00·1 (0·0--0·5)\<0·05 (0·0--0·3)−42·6**Neglected tropical diseases and malaria**24·0 (10·9--65·7)14·9 (4·7--57·6)−45·72·4 (1·0--7·0)1·1 (0·3--4·0)−58·5Malaria0·2 (0·1--0·3)0·1 (0·0--0·1)−63·2\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)−72·1Leishmaniasis6·5 (2·8--14·7)1·8 (0·8--3·6)−71·20·6 (0·2--1·2)0·1 (0·1--0·3)−73·5Schistosomiasis8·5 (0·0--50·4)8·5 (0·0--50·2)0·20·9 (0·0--5·6)0·6 (0·0--3·5)−37·9Cysticercosis\<0·05 (0·0--0·1)\<0·05 (0·0--0·2)54·0\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)3·8Echinococcosis0·6 (0·0--2·3)0·4 (0·0--1·6)−31·50·1 (0·0--0·2)\<0·05 (0·0--0·1)−56·1Dengue1·0 (0·2--3·2)1·0 (0·4--2·3)11·60·1 (0·0--0·3)0·1 (0·0--0·2)−5·6Rabies2·0 (1·2--3·2)1·2 (0·4--2·2)−52·60·2 (0·1--0·3)0·1 (0·0--0·2)−66·1Intestinal nematode infections1·4 (0·0--6·7)0·3 (0·0--1·7)−75·30·1 (0·0--0·5)\<0·05 (0·0--0·2)−69·9Ascariasis1·4 (0·0--6·7)0·3 (0·0--1·7)−75·30·1 (0·0--0·5)\<0·05 (0·0--0·2)−69·9Other neglected tropical diseases3·9 (1·8--5·3)1·5 (0·6--4·1)−73·00·4 (0·2--0·5)0·1 (0·0--0·3)−81·1**Maternal disorders**20·6 (15·9--28·5)5·0 (3·6--6·3)−75·71·6 (1·3--2·2)0·3 (0·2--0·4)−78·2Maternal haemorrhage5·6 (4·4--7·7)1·6 (1·2--2·1)−70·50·4 (0·3--0·6)0·1 (0·1--0·1)−74·4Maternal sepsis3·0 (2·3--4·1)0·7 (0·5--0·9)−75·40·2 (0·2--0·3)0·1 (0·0--0·1)−77·2Hypertensive disorders of pregnancy2·4 (1·9--3·3)0·5 (0·4--0·6)−79·00·2 (0·1--0·3)\<0·05 (0·0--0·05)−80·7Obstructed labour0·2 (0·2--0·3)\<0·05 (0·0--0·1)−74·5\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)−77·5Abortion3·4 (2·6--4·7)0·8 (0·6--1·1)−75·00·3 (0·2--0·4)0·1 (0·0--0·1)−77·4Other maternal disorders6·0 (4·7--8·3)1·2 (0·9--1·5)−79·60·5 (0·4--0·7)0·1 (0·1--0·1)−81·8**Neonatal disorders**343·0 (291·9--394·9)83·4 (61·2--102·7)−75·726·4 (22·5--30·4)9·4 (6·9--11·6)−64·5Preterm birth complications97·4 (69·2--131·7)27·6 (20·0--37·3)−71·67·5 (5·3--10·2)3·1 (2·3--4·2)−58·4Neonatal encephalopathy (birth asphyxia/birth trauma)109·7 (75·2--150·6)26·8 (16·4--39·8)−75·48·5 (5·8--11·6)3·0 (1·9--4·5)−64·0Sepsis and other infectious disorders of the newborn baby5·1 (1·9--11·2)1·6 (0·8--3·2)−65·90·4 (0·1--0·9)0·2 (0·1--0·4)−50·0Other neonatal disorders130·9 (77·9--186·4)27·4 (18·0--40·1)−79·210·1 (6·0--14·4)3·1 (2·0--4·5)−69·6**Nutritional deficiencies**20·0 (16·8--31·9)13·4 (6·8--17·4)−25·22·0 (1·7--3·1)1·1 (0·5--1·4)−40·2Protein-energy malnutrition14·8 (12·2--20·4)9·2 (5·2--12·0)−36·01·5 (1·2--2·0)0·7 (0·4--1·0)−47·5Iodine deficiency0·2 (0·2--0·2)0·2 (0·1--0·3)36·2\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)12·8Iron-deficiency anaemia3·9 (3·3--4·9)2·8 (1·6--3·5)−28·00·4 (0·3--0·5)0·2 (0·1--0·3)−44·9Other nutritional deficiencies1·1 (1·0--1·5)1·2 (0·7--1·6)9·50·1 (0·1--0·2)0·1 (0·1--0·1)−20·6**Other communicable, maternal, neonatal, and nutritional disorders**72·6 (63·1--82·5)69·7 (57·7--78·6)−4·07·0 (6·1--7·8)5·1 (4·1--5·7)−27·6Sexually transmitted diseases excluding HIV19·2 (11·2--27·8)2·7 (1·7--4·3)−86·81·7 (0·9--2·5)0·3 (0·2--0·4)−85·0Syphilis17·0 (10·7--25·2)2·2 (1·3--3·7)−87·21·4 (0·9--2·1)0·2 (0·1--0·4)−84·7Sexually transmitted chlamydial diseases0·5 (0·2--0·9)0·1 (0·1--0·2)−84·10·1 (0·0--0·1)\<0·05 (0·0--0·05)−89·3Gonococcal infection0·4 (0·1--0·7)0·1 (0·1--0·1)−84·0\<0·05 (0·0--0·1)\<0·05 (0·0--0·05)−89·3Other sexually transmitted diseases1·3 (0·4--2·2)0·3 (0·2--0·5)−84·00·1 (0·0--0·2)\<0·05 (0·0--0·05)−89·3Hepatitis33·3 (30·1--36·7)43·8 (37·7--50·7)30·93·4 (3·1--3·8)3·0 (2·5--3·4)−13·5Acute hepatitis A7·0 (3·1--16·9)5·2 (1·8--17·7)−29·40·7 (0·3--1·7)0·4 (0·1--1·2)−53·6Acute hepatitis B21·3 (16·6--27·9)35·1 (23·5--44·1)67·82·3 (1·8--3·0)2·3 (1·6--3·0)7·0Acute hepatitis C0·7 (0·4--1·1)1·2 (0·8--1·6)88·20·1 (0·0--0·1)0·1 (0·1--0·1)16·0Acute hepatitis E4·2 (2·3--7·1)2·3 (1·1--4·1)−47·30·3 (0·2--0·6)0·2 (0·1--0·3)−52·0Other infectious diseases20·1 (16·6--27·2)23·2 (13·0--28·5)22·91·9 (1·6--2·5)1·8 (1·0--2·3)2·5**Non-communicable diseases5937·8 (5679·4--6331·6)7017·1 (6663·3--7310·2)18·7708·5 (678·0--754·9)509·4 (483·6--530·3)--27·8Neoplasms**1503·6 (1362·6--1710·4)2133·5 (1905·4--2314·6)43·1170·0 (154·5--193·7)148·0 (131·9--160·4)−12·0Oesophageal cancer168·8 (138·0--225·8)176·0 (117·9--224·7)10·119·8 (16·1--26·3)12·3 (8·2--15·8)−34·4Stomach cancer297·4 (228·5--403·4)297·0 (209·5--385·3)0·034·3 (26·3--46·6)20·8 (14·7--27·0)−39·2Liver cancer238·6 (199·6--283·9)369·7 (322·0--467·0)54·026·5 (22·3--31·7)25·0 (21·6--31·4)−6·4Liver cancer secondary to hepatitis B128·5 (107·6--153·3)200·8 (170·0--253·6)55·414·3 (12·0--17·0)13·5 (11·4--16·9)−5·6Liver cancer secondary to hepatitis C42·5 (36·1--51·8)71·8 (60·0--89·4)69·84·9 (4·2--6·0)4·9 (4·1--6·1)1·5Liver cancer secondary to alcohol use44·4 (36·2--53·5)67·5 (56·2--87·6)51·44·9 (4·0--5·9)4·5 (3·8--5·8)−8·2Other liver cancer23·3 (19·1--28·5)29·5 (24·3--39·3)25·12·4 (2·0--2·9)1·9 (1·6--2·6)−21·2Larynx cancer9·8 (4·4--18·8)13·5 (5·6--25·3)34·81·1 (0·5--2·2)0·9 (0·4--1·8)−19·3Trachea, bronchus, and lung cancers260·2 (216·2--372·9)513·3 (353·4--598·5)109·530·0 (25·0--43·2)35·8 (24·5--41·8)27·2Breast cancer29·2 (27·9--30·5)52·5 (47·4--59·6)78·43·3 (3·1--3·4)3·5 (3·1--3·9)5·0Cervical cancer20·7 (13·2--30·7)25·4 (12·4--32·5)31·32·4 (1·5--3·5)1·7 (0·8--2·2)−24·5Uterine cancer5·4 (3·7--11·8)10·5 (3·7--13·8)139·30·6 (0·4--1·3)0·7 (0·3--0·9)42·8Prostate cancer3·9 (2·4--7·0)11·3 (4·7--17·6)138·20·5 (0·3--0·9)0·9 (0·4--1·3)43·7Colon and rectum cancers93·0 (76·9--105·2)150·4 (130·5--186·1)59·410·7 (8·9--12·1)10·6 (9·1--13·0)−2·3Mouth cancer7·5 (6·2--8·5)14·0 (10·3--18·4)87·10·9 (0·7--1·0)1·0 (0·7--1·3)12·6Nasopharynx cancer22·1 (15·2--32·4)34·4 (21·1--48·9)49·52·4 (1·7--3·6)2·3 (1·4--3·2)−9·1Cancer of other part of pharynx and oropharynx4·1 (2·5--5·5)5·1 (3·6--8·3)20·90·5 (0·3--0·6)0·3 (0·2--0·6)−26·1Gallbladder and biliary tract cancer17·8 (12·7--27·3)29·8 (19·5--40·5)67·62·1 (1·5--3·2)2·1 (1·4--2·9)1·7Pancreatic cancer32·1 (24·9--43·1)58·2 (43·2--74·8)82·93·7 (2·9--5·0)4·0 (3·0--5·2)9·4Malignant melanoma of skin2·7 (1·4--3·4)6·7 (4·5--11·4)131·50·3 (0·2--0·4)0·5 (0·3--0·8)45·8Non-melanoma skin cancer3·2 (1·5--5·8)4·5 (2·4--8·1)41·10·4 (0·2--0·7)0·3 (0·2--0·6)−15·7Ovarian cancer14·4 (9·8--18·4)20·7 (13·6--29·1)34·41·6 (1·1--2·0)1·4 (0·9--1·9)−18·7Testicular cancer1·0 (0·5--1·4)0·8 (0·4--1·5)−18·30·1 (0·0--0·1)0·1 (0·0--0·1)−43·5Kidney and other urinary organ cancers13·7 (9·9--19·5)32·0 (22·5--41·4)134·91·5 (1·1--2·2)2·2 (1·6--2·9)47·2Bladder cancer14·5 (12·3--18·6)22·9 (17·6--28·2)59·21·8 (1·5--2·2)1·7 (1·3--2·1)−4·2Brain and nervous system cancers35·5 (23·1--48·4)48·9 (29·3--67·1)38·03·8 (2·5--5·2)3·3 (2·0--4·6)−11·5Thyroid cancer4·8 (3·7--6·5)8·1 (5·7--10·6)69·50·5 (0·4--0·7)0·6 (0·4--0·7)4·9Hodgkin\'s disease1·5 (1·0--2·2)1·2 (0·7--1·7)−20·20·1 (0·1--0·2)0·1 (0·1--0·1)−43·0Non-Hodgkin lymphoma21·0 (17·8--24·3)27·7 (22·6--33·7)30·32·2 (1·9--2·6)2·0 (1·6--2·4)−13·9Multiple myeloma5·1 (3·5--7·8)9·4 (5·4--13·3)90·20·5 (0·4--0·8)0·7 (0·4--0·9)21·4Leukaemia53·0 (42·3--67·5)58·0 (44·2--69·2)13·74·9 (3·9--6·2)4·2 (3·2--5·0)−10·5Other neoplasms122·5 (84·9--149·0)131·6 (95·7--171·3)6·313·4 (9·3--16·4)9·2 (6·7--11·9)−32·1**Cardiovascular and circulatory diseases**2167·5 (2054·9--2462·4)3136·2 (2827·1--3274·6)47·4267·7 (253·5--304·4)230·8 (207·4--241·1)−12·2Rheumatic heart disease131·4 (120·1--147·3)57·1 (49·8--63·0)−56·414·9 (13·7--16·8)4·0 (3·5--4·5)−72·7Ischaemic heart disease450·3 (409·2--594·5)948·7 (774·5--1024·6)120·355·7 (50·6--73·9)70·1 (57·2--76·0)31·6Cerebrovascular disease1340·6 (1237·6--1623·2)1726·7 (1463·2--1848·6)34·5167·0 (154·5--201·6)126·9 (107·9--135·8)−20·8Ischaemic stroke426·4 (304·4--639·7)609·6 (478·3--808·4)44·756·3 (40·8--83·3)46·7 (36·7--61·6)−16·2Haemorrhagic and other non-ischemic stroke914·2 (657·9--1146·4)1117·2 (887·1--1359·1)22·1110·7 (79·1--139·5)80·2 (63·8--97·9)−27·7Hypertensive heart disease133·7 (106·7--174·0)172·9 (136·4--210·6)31·516·9 (13·4--21·8)12·8 (10·1--15·7)−22·8Cardiomyopathy and myocarditis32·6 (20·4--48·1)35·2 (24·5--49·5)8·83·6 (2·3--5·1)2·5 (1·8--3·6)−28·5Atrial fibrillation and flutter4·8 (1·9--10·3)12·9 (5·6--26·6)175·10·6 (0·2--1·5)1·0 (0·4--2·1)58·7Aortic aneurysm36·3 (12·9--62·6)58·2 (30·7--90·3)61·44·5 (1·6--7·8)4·3 (2·2--6·6)−3·9Peripheral vascular disease3·3 (1·2--6·6)9·1 (4·1--17·2)180·40·4 (0·1--0·9)0·7 (0·3--1·3)63·7Endocarditis9·5 (6·8--12·8)12·4 (9·8--15·8)31·61·0 (0·7--1·3)0·9 (0·7--1·1)−8·4Other cardiovascular and circulatory diseases25·0 (20·1--31·1)103·0 (94·5--112·6)318·53·1 (2·5--3·9)7·5 (6·9--8·3)148·6**Chronic respiratory diseases**1496·5 (1444·7--1550·5)1022·9 (965·4--1089·3)−31·8189·0 (182·1--196·2)77·2 (72·8--82·3)−59·3Chronic obstructive pulmonary disease1426·9 (1340·1--1509·5)934·4 (846·6--1032·3)−34·3180·7 (169·9--190·9)70·6 (64·0--78·1)−60·8Pneumoconiosis6·1 (3·6--10·6)4·1 (1·9--7·2)−32·70·7 (0·4--1·3)0·3 (0·1--0·5)−59·1Asthma25·2 (16·9--34·8)19·9 (16·6--27·3)−22·23·1 (2·1--4·3)1·5 (1·2--2·0)−52·7Interstitial lung disease and pulmonary sarcoidosis5·0 (2·8--8·0)8·6 (4·8--12·9)73·60·6 (0·3--0·9)0·6 (0·3--0·9)6·9Other chronic respiratory diseases33·4 (25·8--43·2)55·9 (33·6--69·0)72·44·0 (3·0--5·2)4·2 (2·6--5·2)9·2**Cirrhosis of the liver**174·9 (127·0--198·9)114·4 (90·0--187·8)−45·719·6 (14·2--22·3)7·7 (6·1--12·7)−67·3Cirrhosis of the liver secondary to hepatitis B78·7 (55·0--93·1)52·3 (39·3--86·5)−44·19·0 (6·2--10·6)3·5 (2·7--5·9)−66·7Cirrhosis of the liver secondary to hepatitis C37·9 (25·9--44·5)24·5 (18·8--40·7)−45·24·4 (3·0--5·2)1·7 (1·3--2·8)−67·5Cirrhosis of the liver secondary to alcohol use35·9 (24·2--43·7)25·3 (18·8--42·9)−41·04·0 (2·7--4·9)1·7 (1·3--2·9)−64·5Other cirrhosis of the liver22·4 (15·5--26·9)12·3 (9·0--20·8)−54·22·3 (1·6--2·8)0·8 (0·6--1·4)−70·5**Digestive diseases (except cirrhosis)**163·4 (142·8--181·2)133·0 (116·8--153·1)−19·019·1 (16·7--21·2)9·7 (8·5--11·2)−49·4Peptic ulcer disease54·9 (41·4--61·0)19·3 (16·5--23·2)−65·46·5 (4·9--7·3)1·4 (1·2--1·7)−78·9Gastritis and duodenitis2·5 (1·2--5·7)1·3 (0·8--2·7)−43·80·3 (0·1--0·7)0·1 (0·1--0·2)−64·1Appendicitis5·6 (3·3--7·7)1·4 (0·9--2·5)−76·70·6 (0·4--0·8)0·1 (0·1--0·2)−84·2Paralytic ileus and intestinal obstruction without hernia17·3 (9·7--21·7)11·2 (7·8--18·9)−44·61·9 (1·1--2·3)0·8 (0·6--1·4)−62·0Inguinal or femoral hernia2·0 (1·9--2·0)1·1 (1·0--1·1)−43·40·2 (0·2--0·2)0·1 (0·1--0·1)−65·9Non-infective inflammatory bowel disease2·8 (1·0--4·9)2·4 (1·2--3·9)−10·00·3 (0·1--0·5)0·2 (0·1--0·3)−38·9Vascular disorders of intestine6·0 (1·8--17·6)10·3 (3·8--26·5)86·00·7 (0·2--2·2)0·8 (0·3--2·0)11·6Gall bladder and bile duct disease15·5 (11·3--21·1)18·2 (11·5--27·1)16·51·8 (1·3--2·5)1·3 (0·8--2·0)−26·4Pancreatitis6·2 (3·2--9·6)8·3 (5·2--11·5)34·70·7 (0·4--1·1)0·6 (0·4--0·8)−18·0Other digestive diseases50·7 (33·2--63·2)59·5 (45·7--91·5)11·16·0 (3·9--7·5)4·3 (3·3--6·6)−31·1**Neurological disorders**58·5 (46·1--74·8)80·6 (65·1--112·4)34·56·5 (5·1--8·3)6·1 (4·9--8·5)−8·9Alzheimer\'s disease and other dementias25·8 (17·0--35·8)50·0 (36·8--77·6)87·93·4 (2·2--4·8)3·9 (2·8--6·1)13·0Parkinson\'s disease4·1 (2·4--5·9)7·3 (4·7--11·3)73·60·5 (0·3--0·7)0·5 (0·3--0·8)9·5Epilepsy18·7 (12·0--23·0)12·2 (10·4--17·8)−37·31·7 (1·1--2·0)0·9 (0·7--1·3)−50·1Multiple sclerosis3·2 (1·3--5·3)1·6 (1·0--2·6)−54·20·3 (0·1--0·6)0·1 (0·1--0·2)−71·8Other neurological disorders6·6 (3·6--17·1)9·5 (5·3--18·8)53·90·7 (0·4--1·6)0·7 (0·4--1·4)12·6**Mental and behavioural disorders**23·3 (15·0--30·0)20·7 (16·7--29·8)−16·92·4 (1·6--3·1)1·4 (1·1--2·1)−44·4Schizophrenia12·6 (8·3--16·0)8·9 (7·1--14·1)−33·41·3 (0·9--1·7)0·6 (0·5--1·0)−57·7Alcohol use disorders3·3 (1·7--7·1)4·6 (2·3--8·2)44·60·3 (0·2--0·7)0·3 (0·2--0·5)−7·8Drug use disorders3·2 (0·5--6·6)4·8 (3·2--10·5)41·30·3 (0·1--0·6)0·3 (0·2--0·8)12·8Opioid use disorders1·0 (0·2--2·0)1·5 (1·0--3·4)45·10·1 (0·0--0·2)0·1 (0·1--0·3)15·6Cocaine use disorders0·1 (0·0--0·3)\<0·05 (0·0--0·05)−96·7\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)−97·4Amphetamine use disorders0·1 (0·0--0·1)\<0·05 (0·0--0·05)−93·4\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)−94·7Other drug use disorders2·0 (0·3--4·1)3·2 (2·1--6·7)53·50·2 (0·0--0·4)0·2 (0·2--0·5)22·3Eating disorders1·5 (0·4--2·6)0·7 (0·5--1·4)−69·10·1 (0·0--0·3)0·1 (0·0--0·1)−76·9Other mental and behavioural disorders2·7 (0·8--4·7)1·6 (1·0--3·2)−63·40·3 (0·1--0·5)0·1 (0·1--0·2)−74·8**Diabetes, urogenital, blood, and endocrine diseases**186·2 (158·2--245·1)294·9 (252·1--323·1)65·320·6 (17·6--27·3)21·3 (18·2--23·3)7·9Diabetes mellitus70·5 (64·2--102·4)160·1 (123·7--176·2)141·68·0 (7·3--11·8)11·5 (8·8--12·7)52·3Acute glomerulonephritis16·2 (1·7--61·4)3·0 (1·1--6·4)−72·01·7 (0·2--6·5)0·2 (0·1--0·5)−80·5Chronic kidney diseases53·9 (47·6--75·5)82·0 (66·6--93·1)62·06·0 (5·3--8·4)5·8 (4·7--6·6)2·5Chronic kidney disease due to diabetes mellitus8·8 (7·2--12·6)14·5 (11·5--17·4)75·91·0 (0·8--1·5)1·0 (0·8--1·2)5·7Chronic kidney disease due to hypertension10·5 (9·0--14·9)16·6 (13·3--19·2)66·81·2 (1·0--1·7)1·2 (0·9--1·4)3·4Chronic kidney disease unspecified34·6 (30·0--48·5)51·0 (41·3--58·7)57·13·8 (3·3--5·3)3·6 (2·9--4·2)1·5Urinary diseases and male infertility14·8 (7·9--20·1)13·0 (9·8--20·1)−19·41·7 (0·9--2·3)1·0 (0·7--1·5)−47·8Tubulointerstitial nephritis, pyelonephritis, and urinary tract infections7·8 (4·5--11·0)8·5 (6·4--12·7)7·70·9 (0·5--1·2)0·6 (0·5--0·9)−27·7Urolithiasis5·6 (2·3--12·5)3·0 (0·9--7·8)−46·90·7 (0·3--1·5)0·2 (0·1--0·6)−67·3Other urinary diseases1·5 (0·8--2·0)1·5 (1·1--2·5)−3·70·2 (0·1--0·2)0·1 (0·1--0·2)−40·0Gynaecological diseases2·7 (2·0--3·7)1·7 (1·3--2·2)−38·30·3 (0·2--0·4)0·1 (0·1--0·2)−58·3Uterine fibroids\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)−76·8\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)−75·2Endometriosis0·0 (0·0--0·0)0·0 (0·0--0·0)0·00·0 (0·0--0·0)0·0 (0·0--0·0)0·0Genital prolapse0·1 (0·0--0·1)\<0·05 (0·0--0·05)−36·1\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)−58·9Other gynaecological diseases2·6 (1·9--3·7)1·6 (1·3--2·2)−38·20·3 (0·2--0·4)0·1 (0·1--0·1)−58·1Haemoglobinopathies and haemolytic anaemias20·5 (8·1--39·0)15·2 (8·5--24·5)−23·62·1 (0·8--4·0)1·2 (0·6--1·8)−43·8Thalassaemias7·5 (4·3--13·5)3·7 (2·7--4·8)−49·30·6 (0·4--1·1)0·3 (0·2--0·4)−54·8Sickle cell disorders0·1 (0·0--0·1)\<0·05 (0·0--0·05)−43·4\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)−53·2G6PD deficiency0·8 (0·5--1·5)0·6 (0·5--0·8)−21·90·1 (0·1--0·1)\<0·05 (0·0--0·1)−42·3Other haemoglobinopathies and haemolytic anaemias12·1 (4·3--25·2)10·8 (4·5--20·1)−4·31·4 (0·5--2·9)0·8 (0·3--1·6)−36·6Other endocrine, nutritional, blood, and immune disorders7·5 (4·7--13·3)20·0 (10·7--30·7)176·80·7 (0·5--1·4)1·5 (0·8--2·3)119·2**Musculoskeletal disorders**17·3 (9·7--22·4)26·2 (19·3--40·7)41·22·0 (1·1--2·5)1·9 (1·4--2·9)−11·2Rheumatoid arthritis8·9 (5·2--11·8)11·3 (7·9--16·6)22·91·1 (0·6--1·4)0·8 (0·6--1·2)−24·2Other musculoskeletal disorders8·3 (3·6--12·0)14·9 (11·6--25·1)55·30·9 (0·4--1·3)1·1 (0·8--1·8)2·5**Other non-communicable diseases**146·6 (122·3--195·6)54·8 (42·8--73·6)−62·811·6 (9·7--15·4)5·4 (4·1--7·4)−54·0Congenital anomalies130·1 (106·0--176·9)45·7 (33·5--65·1)−65·010·0 (8·2--13·6)4·6 (3·4--6·7)−53·9Neural tube defects25·0 (11·6--43·5)3·2 (1·7--6·6)−87·51·9 (0·9--3·4)0·3 (0·2--0·7)−82·7Congenital heart anomalies73·4 (63·2--86·0)31·3 (24·6--40·4)−57·55·6 (4·9--6·6)3·2 (2·5--4·1)−44·1Cleft lip and cleft palate4·3 (1·1--11·9)0·7 (0·3--1·5)−81·10·3 (0·1--0·9)0·1 (0·0--0·2)−72·4Down\'s syndrome2·1 (0·9--4·3)0·9 (0·6--1·3)−56·40·2 (0·1--0·3)0·1 (0·1--0·1)−50·1Other chromosomal abnormalities11·4 (2·6--35·8)2·9 (1·3--6·9)−69·50·9 (0·2--2·8)0·3 (0·1--0·8)−58·6Other congenital anomalies14·0 (3·4--32·5)6·8 (4·1--13·6)−43·51·1 (0·3--2·5)0·7 (0·4--1·4)−28·4Skin and subcutaneous diseases12·7 (9·0--15·3)7·4 (5·5--9·0)−41·71·3 (1·0--1·6)0·6 (0·4--0·7)−57·0Cellulitis3·4 (2·4--4·2)1·6 (1·3--1·9)−53·10·3 (0·2--0·4)0·1 (0·1--0·1)−64·6Abscess, impetigo, and other bacterial skin diseases5·5 (3·6--6·9)2·3 (1·8--2·7)−58·40·5 (0·4--0·6)0·2 (0·1--0·2)−66·6Decubitus ulcer3·7 (2·9--4·7)3·5 (2·4--4·5)−7·70·5 (0·4--0·6)0·3 (0·2--0·4)−41·4Other skin and subcutaneous diseases\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)−64·6\<0·05 (0·0--0·05)\<0·05 (0·0--0·05)−69·8Sudden infant death syndrome3·8 (0·8--15·1)1·6 (0·5--4·3)−49·60·3 (0·1--1·1)0·2 (0·1--0·5)−26·8**Injuries851·9 (738·8--968·8)796·2 (697·4--992·5)--9·978·9 (68·7--89·3)56·7 (49·8--70·4)--30·5Transport injuries**159·5 (108·6--245·1)287·0 (204·7--415·0)79·014·7 (9·8--22·3)19·8 (14·2--28·6)33·5Road injury155·5 (105·5--231·8)282·6 (205·2--414·9)90·314·3 (9·7--21·2)19·5 (14·2--28·6)42·4Pedestrian injury by road vehicle34·7 (16·1--57·7)105·4 (75·3--142·1)188·93·2 (1·5--5·3)7·2 (5·2--9·6)113·8Pedal cycle vehicle6·0 (3·3--9·9)8·8 (4·8--13·0)48·20·6 (0·3--0·9)0·6 (0·3--0·9)11·2Motorised vehicle with two wheels33·2 (18·5--51·8)48·7 (37·5--62·1)48·63·0 (1·7--4·7)3·3 (2·6--4·2)12·4Motorised vehicle with three or more wheels34·5 (21·0--48·7)74·0 (55·2--92·9)111·53·1 (1·9--4·5)5·1 (3·8--6·4)59·8Road injury other47·1 (9·8--114·0)45·7 (10·1--122·0)−5·84·4 (0·9--10·6)3·2 (0·7--8·6)−28·0Other transport injury4·0 (1·9--6·5)4·4 (2·5--7·2)7·30·4 (0·2--0·6)0·3 (0·2--0·5)−18·3**Unintentional injuries other than transport injuries**458·6 (412·0--508·7)316·4 (277·2--349·5)−30·741·9 (38·2--46·4)23·6 (20·7--26·1)−43·6Falls88·1 (75·4--109·8)115·3 (89·1--136·0)32·99·7 (8·2--12·2)8·5 (6·6--10·0)−11·7Drowning147·4 (107·8--175·8)67·4 (56·7--93·2)−56·512·2 (9·1--14·4)5·5 (4·5--7·7)−57·4Fire, heat, and hot substances15·8 (12·7--19·9)10·7 (8·4--15·4)−33·71·6 (1·3--2·0)0·8 (0·6--1·2)−51·5Poisonings52·7 (39·6--93·6)37·0 (19·3--49·0)−14·54·9 (3·7--8·8)2·6 (1·4--3·4)−37·1Exposure to mechanical forces30·8 (23·1--44·0)21·0 (12·2--27·0)−28·02·8 (2·1--4·1)1·4 (0·8--1·8)−45·2Mechanical forces (firearm)11·4 (4·8--19·6)3·6 (1·5--6·8)−69·31·0 (0·4--1·8)0·2 (0·1--0·5)−76·2Mechanical forces (other)19·4 (9·3--36·9)17·4 (7·1--28·0)−5·81·8 (0·8--3·4)1·2 (0·5--1·9)−28·8Adverse effects of medical treatment4·2 (1·9--7·0)7·0 (4·3--10·2)72·40·4 (0·2--0·6)0·5 (0·3--0·8)34·1Animal contact8·0 (3·4--14·5)3·0 (1·3--5·3)−61·70·8 (0·3--1·4)0·2 (0·1--0·4)−71·0Animal contact (venomous)3·5 (1·2--9·1)1·2 (0·5--2·5)−60·80·3 (0·1--0·9)0·1 (0·0--0·2)−71·2Animal contact (non-venomous)4·5 (1·5--9·6)1·8 (0·8--3·4)−59·30·4 (0·1--0·9)0·1 (0·1--0·3)−68·1Unintentional injuries not classified elsewhere111·6 (81·2--128·8)55·0 (39·9--62·4)−50·89·5 (7·0--10·8)4·1 (3·1--4·7)−56·9**Self-harm and interpersonal violence**233·7 (157·5--278·0)192·9 (152·2--309·3)−29·422·3 (15·4--26·7)13·4 (10·5--21·3)−48·5Self-harm206·1 (132·3--248·9)173·0 (134·6--286·0)−28·520·0 (13·1--24·6)12·0 (9·3--19·7)−48·6Interpersonal violence27·7 (18·5--35·4)19·9 (15·3--33·3)−36·02·3 (1·6--3·0)1·4 (1·1--2·3)−47·0Assault by firearm4·9 (2·0--10·3)2·2 (1·2--3·9)−54·70·4 (0·2--0·9)0·1 (0·1--0·3)−63·8Assault by sharp object7·3 (3·6--12·0)6·1 (3·9--9·7)−13·20·6 (0·3--1·0)0·4 (0·3--0·7)−27·7Assault by other means15·5 (10·1--21·5)11·7 (7·5--17·4)−23·91·3 (0·9--1·8)0·8 (0·5--1·2)−36·9[^3]

China has made substantial progress in reduction of the number of child deaths from 1·0 million (95% UI 0·9--1·1 million) in 1990 to 213 0000 (179 600--260 700) in 2010 ([table 3](#tbl3){ref-type="table"} ). During this period, the main causes of child mortality also changed. The top five specific causes, accounting for 59·7% (51·7--69·1) of child deaths in 2010 were (in order of frequency) congenital anomalies, preterm birth complications, lower respiratory infections, neonatal encephalopathy, and drowning. Diarrhoeal diseases were ranked sixth (95% UI fifth to seventh) in 1990 but accounted for 0·9% (95% UI 0·6--1·3) of child deaths in 2010, and measles were ranked seventh (sixth to 13th) in 1990 but accounted for 0·2% (95% UI \<0·05--0·4) of child deaths in 2010.Table 3Deaths (in thousands), percentage of all-cause mortality, and median percentage change by cause from 1990 to 2010 for children younger than 5 years (both sexes) in China**19902010Median %Δ in deaths**Deaths (thousands)% of totalDeaths (thousands)% of totalAll causes1038·9 (927·4 to 1136·5)..213·0 (179·6 to 260·7)..−79·7 (−83·2 to −73·5)Congenital anomalies109·6 (87·5 to 153·2)10·6 (8·6 to 14·4)33·2 (23·0 to 50·1)15·5 (11·3 to 19·9)−69·7 (−81·8 to −49·7)Preterm birth complications97·4 (69·2 to 131·7)9·4 (6·6 to 13·1)27·6 (20·0 to 37·3)13·0 (9·2 to 18·0)−71·6 (−81·6 to −57·7)Other neonatal disorders130·9 (77·9 to 186·4)12·6 (7·4 to 18·7)27·4 (18·0 to 40·1)13·0 (8·2 to 19·4)−79·2 (−87·7 to −61·3)Lower respiratory infections254·7 (199·2 to 298·4)24·5 (20·0 to 27·7)26·9 (20·6 to 37·4)12·7 (9·5 to 17·4)−89·9 (−92·3 to −83·9)Neonatal encephalopathy (birth asphyxia/birth trauma)109·7 (75·2 to 150·6)10·6 (7·2 to 14·8)26·8 (16·4 to 39·8)12·6 (7·7 to 18·9)−75·4 (−86·4 to −60·2)Other non-communicable diseases48·1 (37·0 to 64·5)4·6 (3·7 to 6·2)19·7 (16·1 to 24·2)9·3 (7·4 to 11·6)−58·8 (−69·5 to −44·7)Drowning63·2 (36·3 to 87·6)6·1 (3·8 to 8·1)12·5 (7·6 to 25·2)5·8 (3·8 to 10·4)−81·9 (−89·4 to −42·8)Other injuries64·5 (46·6 to 79·3)6·2 (4·7 to 7·7)11·2 (8·2 to 14·6)5·3 (3·7 to 7·0)−82·7 (−87·4 to −74·5)Other communicable, maternal, neonatal, and nutritional diseases12·3 (7·4 to 21·8)1·2 (0·7 to 2·1)6·0 (3·3 to 8·4)2·8 (1·5 to 4·1)−46·3 (−80·3 to −10·3)Road injury9·0 (5·5 to 15·0)0·9 (0·5 to 1·4)5·5 (3·5 to 9·2)2·6 (1·6 to 4·2)−38·9 (−69·8 to 38·0)Falls7·1 (5·0 to 12·0)0·7 (0·5 to 1·1)2·7 (1·7 to 4·2)1·3 (0·8 to 1·9)−59·4 (−82·3 to −28·8)Meningitis and encephalitis13·6 (10·6 to 17·9)1·3 (1·0 to 1·8)2·1 (1·4 to 2·8)1·0 (0·6 to 1·4)−85·1 (−90·1 to −78·0)Diarrhoeal diseases47·4 (37·9 to 58·8)4·6 (3·7 to 5·7)1·9 (1·4 to 2·7)0·9 (0·6 to 1·3)−95·9 (−97·2 to −93·8)Syphilis12·2 (6·8 to 19·9)1·2 (0·6 to 1·9)1·7 (0·8 to 3·1)0·8 (0·4 to 1·5)−86·8 (−91·6 to −78·7)Sepsis and other infectious disorders of the newborn baby5·1 (1·9 to 11·2)0·5 (0·2 to 1·1)1·6 (0·8 to 3·2)0·8 (0·4 to 1·5)−65·9 (−88·3 to −21·8)Typhoid and paratyphoid fevers2·4 (0·3 to 4·5)0·2 (\<0·05 to 0·4)1·6 (0·2 to 3·1)0·7 (0·1 to 1·5)−33·6 (−54·1 to −1·2)Nutritional deficiencies6·1 (4·1 to 12·3)0·6 (0·4 to 1·2)1·4 (0·5 to 2·2)0·7 (0·2 to 1·1)−74·2 (−94·8 to −54·5)Tetanus15·3 (7·4 to 27·1)1·5 (0·7 to 2·5)0·7 (0·3 to 1·7)0·3 (0·1 to 0·8)−96·0 (−98·2 to −86·7)Fire, heat, and hot substances3·1 (2·0 to 4·6)0·3 (0·2 to 0·4)0·7 (0·4 to 1·3)0·3 (0·2 to 0·6)−80·7 (−89·0 to −46·2)Epilepsy1·6 (0·8 to 3·0)0·2 (0·1 to 0·3)0·5 (0·3 to 0·9)0·3 (0·2 to 0·4)−65·6 (−84·3 to −17·6)Whooping cough3·2 (\<0·05 to 15·8)0·3 (\<0·05 to 1·5)0·4 (\<0·05 to 2·0)0·2 (\<0·05 to 1·0)−87·1 (−89·0 to −84·5)HIV/AIDS\<0·05 (\<0·05 to 0·05)\<0·05 (\<0·05 to 0·05)0·4 (0·2 to 0·6)0·2 (0·1 to 0·3)4232·1 (1493·7 to 46 693·7)Measles20·0 (6·6 to 50·9)1·9 (0·6 to 4·8)0·3 (0·1 to 0·9)0·2 (\<0·05 to 0·4)−98·4 (−99·0 to −97·3)Tuberculosis2·5 (1·8 to 3·2)0·2 (0·2 to 0·3)0·2 (0·1 to 0·4)0·1 (\<0·05 to 0·2)−91·3 (−96·1 to −84·1)[^4]

[Figure 2](#fig2){ref-type="fig"} shows the striking transition in YLLs that took place in China between 1990 and 2010. The number of YLLs attributable to neonatal causes, diarrhoea, pneumonia, and other infectious causes and injuries in children declined profoundly in this period. At the same time, a shift occurred towards a large number of cardiovascular and cancer YLLs at older ages with a notable peak in cancer YLLs in the 55--59 year age group in 2010. The number, age pattern, and composition of injury YLLs also changed: we noted increases and shifts to older ages in transport injuries and large declines in intentional injuries.Figure 2Years of life lost in China for both sexes for 21 cause groups, by age(A) 1990. (B) 2010.

[Figure 3](#fig3){ref-type="fig"} shows the transition in leading causes of YLLs from 1990 to 2010. We noted striking declines in major communicable and neonatal causes of premature mortality: lower respiratory infections moved from first (95% UI first to third) to ninth (eighth to 11th); neonatal encephalopathy dropped 14 ranks (sixth to 20th); preterm birth complications dropped ten ranks (ninth to 19th); a 77% (95% UI 72--84) decline in YLLs from tuberculosis led it to drop from 15th (13th to 16th) to 29th (26th to 35th); and diarrhoea and meningitis also had substantial improvements. YLLs from stroke, ischaemic heart disease, road injury, lung cancer, liver cancer, colorectal cancer, and diabetes increased. Although population ageing was a key driver of these increases, age-standardised YLL rates (data not shown) for ischaemic heart disease, road injury, lung cancer, and diabetes also increased between 1990 and 2010. Several disorders that did not increase in incidence remained leading causes of YLLs in 2010: chronic obstructive pulmonary disease, stomach cancer, self-harm, oesophageal cancer, drowning, falls, and congenital anomalies. The substantial decrease we noted in premature mortality from drowning deserves note. Incidence of HIV/AIDS increased strikingly in the 20-year period to become the 23rd biggest cause (20th to 29th) of YLLs.Figure 3Ranks for the top 25 causes of years of life lost in China for both sexes and all ages combined with 95% UIs in 1990 and 2010 and median percentage change from 1990 to 2010UI=uncertainty interval. COPD=chronic obstructive pulmonary disease.

[Figure 4](#fig4){ref-type="fig"} shows the levels of premature mortality in China relative to other members of the G20 in 2010. For men in China in 2010, age-standardised rates of years of life lost due to ischaemic heart disease, lower respiratory infections, cirrhosis, diabetes, preterm birth complications, chronic kidney diseases, HIV/AIDS, and tuberculosis were significantly better than the G20 mean. China had significantly worse ranks than the mean for stroke, chronic obstructive pulmonary disease, liver cancer, stomach cancer, oesophageal cancer, leukaemia, drowning, and falls. The YLL rates of road injury and lung cancer for 2010 are indistinguishable from the mean but the absolute increase in YLLs from these causes is concerning. For women in China, we noted better than G20 average performance on ischaemic heart disease, lower respiratory infections, diabetes, breast cancer, preterm birth complications, chronic kidney diseases, cervical cancer, cirrhosis, and cardiovascular and circulatory diseases. We noted worse than G20 average outcomes for stroke, chronic obstructive pulmonary disease, road injury, self-harm, liver cancer, stomach cancer, oesophageal cancer, falls, drowning, and rheumatic heart disease. Even for conditions such as ischaemic heart disease, lung cancer, and diabetes (for which China was better than average in the G20 in 2010), rising rates suggest that this status might change in the near future.Figure 4Age-standardised YLL rates in China in 2010 relative to 18 other members of G20, ranked by cause(A) Male individuals. (B) Female individuals. Numbers in cells show the ranks of each country for each cause, with 1 representing the best performing country. Countries have been sorted on the basis of age-standardised all-cause YLLs for that year. Causes are ordered by the 25 leading causes of YLLs in China. YLL=years of life lost. COPD=chronic obstructive pulmonary disease.

[Appendix p 6](#sec1){ref-type="sec"} shows YLDs per head by age in China, by sex, in 1990 and 2010. Compared with substantial declines in mortality, we noted relatively little change in the age-specific YLDs per head. The percentage of DALYs attributable to YLDs increased from 28·1% (95% UI 24·2--32·5) to 39·4% (34·9--43·8) in 2010. [Figure 5](#fig5){ref-type="fig"} shows the prominent role played by mental and behavioural disorders (23·6%, 18·9--28·6) and musculoskeletal disorders (25·8%, 21·7--29·9) as causes of YLDs in adults. At younger ages, however, nutritional deficiencies, and some neglected tropical diseases make an important contribution. Other important causes included diabetes, urogenital, blood, and endocrine causes; other non-communicable diseases, which includes vision loss, hearing loss, and skin diseases; and unintentional injuries, which includes falls. Although age-specific YLDs per head rise with age, the effect of population age-structure leads to 77·2% (76·5--78·0) of YLDs occurring before age 60 years in China.Figure 5Years lived with disability in China for both sexes for 21 cause groups, by age(A) 1990. (B) 2010.

[Figure 6](#fig6){ref-type="fig"} compares the leading causes of YLDs in 1990 and 2010. The top 11 causes of YLDs all increased in terms of the absolute numbers of YLDs. Of the top ten causes of disability in 2010, four were musculoskeletal disorders (low back pain, neck pain, other musculoskeletal disorders, and osteoarthritis). Major depression was the second leading cause of disability and alcohol use disorders was the ninth most common cause of YLDs. China ranked among the G20 as having the fifth lowest age-standardised rate of major depression. Diabetes, falls, chronic obstructive pulmonary disease, and hearing loss constituted the other top ten causes of YLDs. Progress on tackling communicable diseases was also evident in the analysis of YLDs. We noted substantial declines (\>30·0%) for iron-deficiency anaemia, hookworm, tuberculosis, and ascariasis.Figure 6Top 25 ranks causes of YLDs for both sexes and all ages in China in 1990 and 2010, with median percentage change from 1990 to 2010UI=uncertainty level. COPD=chronic obstructive pulmonary disease. YLDs=years lived with disability.

Putting premature mortality and disability together in terms of DALYs provides an overall picture of the leading health problems in China. [Table 4](#tbl4){ref-type="table"} shows the number and rate of DALYs in 1990 and 2010 and the percentage change between 1990 and 2010. The top ten causes have prominent roles for cardiovascular disorders (stroke and ischaemic heart disease) and cancers (lung and liver). Two disorders that largely cause disability, low back pain and major depression, are also leading causes of DALYs. Four other disorders make up the top ten: chronic obstructive pulmonary disease, diabetes, road injuries, and falls, which all make up an important component of premature mortality and disability.Table 4DALYs (in thousands) for 285 causes in 1990 and 2010 for all ages, both sexes, and per 100 000 with 95% UI and percentage change, in China**All ages DALYs (thousands)Age-standardised DALY rate (per 100 000)**19902010Median %Δ19902010Median %Δ**All causes365 390·8 (342 403·1--390 433·0)316 616·1 (292 429·2--341 996·6)--13·434 627·6 (32 546·7--36 963·9)22 805·6 (21 125·1--24 630·4)--34·2Communicable, maternal, neonatal, and nutritional disorders97 065·4 (87 592·0--108 572·4)32 024·5(28 260·9--36 819·7)--67·07897·2(7130·3--8857·0)2843·8 (2489·4--3247·7)--63·9HIV/AIDS and tuberculosis**6163·8 (5178·9--7105·7)3484·6 (2829·3--4197·3)−43·6620·1 (518·8--715·0)236·1 (191·8--284·2)−62·0Tuberculosis6150·8 (5170·7--7096·4)1732·9 (1352·2--2098·1)−71·5618·9 (517·9--714·7)117·8 (91·7--142·5)−80·8HIV/AIDS13·0 (1·8--31·3)1751·7 (1258·8--2330·9)12 400·01·2 (0·2--2·9)118·2 (84·8--157·5)9009·4HIV disease resulting in mycobacterial infection1·3 (0·1--3·5)113·8 (83·2--147·9)7451·50·1 (0·0--0·3)7·7 (5·6--10·0)5439·7HIV disease resulting in other specified or unspecified diseases11·7 (1·8--27·7)1637·9 (1173·2--2184·2)12 995·81·1 (0·2--2·6)110·6 (78·8--147·2)9483·0**Diarrhoea, lower respiratory infections, meningitis, and other common infectious diseases**39 694·8(33 504·7--44 936·4)9202·9(7907·1--10 842·0)−77·03162·3 (2698·5--3559·1)805·6(691·9--947·5)−74·7Diarrhoeal diseases6016·0 (5080·9--7135·2)1297·4 (923·5--1752·6)−78·7478·3 (405·4--564·6)115·6 (83·0--155·3)−76·0Cholera178·2 (104·9--301·2)15·4 (9·1--25·5)−91·513·6 (8·1--22·9)1·5 (0·9--2·5)−89·1Other salmonella infections411·5 (281·4--593·8)73·0 (46·4--107·2)−82·332·7 (22·7--46·4)6·3 (4·0--9·4)−80·9Shigellosis402·8 (289·3--557·6)109·8 (68·1--170·7)−72·832·9 (24·1--45·1)9·2 (5·7--14·5)−72·3Enteropathogenic *E coli* infection680·0 (427·6--1019·6)132·3 (70·6--232·2)−81·151·9 (32·8--77·6)13·6 (7·1--24·3)−74·7Enterotoxigenic *E coli* infection534·9 (393·2--728·3)189·4 (121·4--300·3)−64·844·1 (32·9--59·1)15·5 (9·8--25·0)−65·5Campylobacter enteritis590·2 (384·8--882·4)125·9 (72·7--204·4)−78·946·2 (30·5--68·5)11·7 (6·5--19·6)−75·1Amoebiasis101·4 (72·2--140·4)36·2 (21·2--56·5)−64·59·1 (6·6--12·2)2·7 (1·6--4·1)−71·1Cryptosporidiosis554·2 (357·6--831·1)88·3 (47·3--147·7)−84·442·3 (27·4--63·2)8·9 (4·7--15·2)−79·5Rotaviral enteritis1567·4 (1150·5--2046·1)230·2 (149·7--340·7)−85·4120·9 (89·2--157·4)22·6 (14·3--33·9)−81·5Other diarrhoeal diseases995·5 (671·2--1385·3)296·9 (156·1--476·9)−70·684·6 (58·1--117·1)23·6 (12·4--38·4)−72·6Typhoid and paratyphoid fevers772·9 (96·8--1455·1)682·9 (89·7--1255·7)−11·662·0 (7·8--116·7)57·2 (7·5--105·9)−7·8Lower respiratory infections25 300·9(20 527·7--29 014·8)5135·0(4492·8--6092·5)−80·12006·9 (1648·0--2285·2)464·7(401·2--565·5)−77·4Influenza4671·2 (3519·9--5865·6)1067·1 (909·2--1282·3)−77·3374·6 (287·9--465·0)93·7 (78·1--115·1)−75·2Pneumococcal pneumonia4839·2 (3770·6--6127·1)1235·2 (1057·1--1457·0)−74·6394·6 (314·7--492·9)106·0 (89·1--127·0)−73·3*H influenzae* type B pneumonia7623·1 (5682·2--9727·9)1192·7 (950·1--1534·7)−84·7590·6 (443·6--748·8)114·5 (88·6--151·5)−81·1Respiratory syncytial virus pneumonia4723·5 (3295·0--6322·1)512·1 (348·0--745·3)−89·5359·4 (250·9--480·7)55·7 (37·5--81·6)−84·9Other lower respiratory infections3444·0 (2318·6--5218·0)1127·8 (918·1--1404·1)−66·4287·8 (201·3--425·4)94·7 (75·6--120·4)−66·5Upper respiratory infections231·5 (127·1--387·5)212·1 (105·4--371·5)−9·319·4 (10·6--32·6)16·6 (8·2--28·9)−15·6Otitis media1012·8 (573·6--1805·1)893·4 (533·8--1422·2)−8·390·2 (51·9--158·2)69·0 (41·2--108·0)−21·4Meningitis2229·3 (1863·5--2559·9)674·6 (534·6--890·1)−70·1186·6 (155·8--214·1)53·9 (43·3--69·2)−71·5Pneumococcal meningitis443·1 (348·3--526·5)127·9 (97·5--166·5)−71·737·2 (29·5--44·2)10·0 (7·7--12·8)−73·7*H influenzae* type B meningitis407·0 (328·9--502·0)88·0 (68·1--110·4)−78·532·4 (26·3--39·5)8·0 (6·2--10·1)−75·4Meningococcal infection303·9 (238·9--364·9)84·4 (65·5--110·0)−72·725·2 (19·9--30·1)6·7 (5·2--8·6)−73·8Other meningitis1072·1 (868·3--1259·7)372·4 (286·5--504·6)−65·891·4 (73·9--108·1)29·0 (22·6--38·1)−68·7Encephalitis312·5 (260·7--377·3)67·7 (53·8--84·7)−78·424·7 (20·7--29·6)6·1 (4·8--7·6)−75·5Diphtheria12·2 (0·0--107·6)2·9 (0·0--24·8)−76·30·9 (0·0--8·3)0·3 (0·0--2·4)−70·0Whooping cough290·1 (9·5--1396·2)39·7 (1·8--182·8)−85·822·0 (0·7--106·0)4·3 (0·2--19·7)−79·8Tetanus1457·4 (697·9--2530·1)90·2 (34·2--227·9)−94·4114·1 (54·9--197·3)8·7 (3·6--21·2)−92·9Measles1975·7 (666·8--5000·0)33·8 (9·3--93·2)−98·3149·6 (50·5--378·7)3·6 (1·0--9·9)−97·7Varicella83·5 (22·7--346·5)73·2 (29·0--221·1)6·27·4 (2·2--28·6)5·7 (2·1--19·1)−16·8**Neglected tropical diseases and malaria**8656·2(5002·0--16 670·9)3697·5(1947·9--7386·2)−58·0762·1(441·2--1459·8)287·4(155·1--553·1)−62·5Malaria15·2 (10·5--22·2)11·7 (7·2--18·3)−22·81·3 (0·9--1·9)1·0 (0·6--1·5)−25·0Leishmaniasis426·5 (187·3--970·8)110·2 (52·8--212·1)−73·834·6 (15·4--77·6)9·4 (4·3--18·7)−72·7Schistosomiasis273·4 (13·1--1548·5)250·6 (20·8--1344·8)−0·727·8 (1·1--158·5)17·5 (1·9--90·8)−26·8Cysticercosis104·8 (73·3--148·9)67·5 (44·0--96·5)−35·69·3 (6·6--13·0)4·7 (3·0--6·7)−49·9Echinococcosis41·7 (7·9--121·2)44·9 (9·0--144·0)−1·34·1 (0·8--11·9)3·1 (0·6--9·8)−30·5Lymphatic filariasis123·5 (76·7--180·5)−100·011·6 (7·2--16·9)−100·0Trachoma25·9 (16·3--38·6)39·9 (25·9--56·8)55·22·8 (1·8--4·2)2·7 (1·8--3·8)−4·7Dengue57·2 (12·5--196·5)47·2 (18·9--112·2)−8·34·7 (1·0--16·0)4·0 (1·5--9·5)−8·8Rabies94·3 (53·7--156·2)45·1 (13·3--84·5)−60·18·4 (4·9--13·7)3·4 (1·0--6·4)−66·5Intestinal nematode infections4431·0 (2391·4--7631·5)1043·0 (459·1--1991·9)−76·6389·3 (211·0--672·4)92·0 (39·0--174·5)−76·3Ascariasis2152·3 (1169·7--3626·8)90·8 (43·4--195·4)−96·1190·1 (103·5--321·0)7·5 (3·4--17·1)−96·5Trichuriasis237·8 (126·8--402·5)14·1 (7·7--25·2)−94·121·1 (11·3--35·4)1·1 (0·6--1·9)−95·0Hookworm disease2040·9 (960·6--3650·7)938·1 (387·0--1831·4)−54·3178·1 (85·0--319·1)83·4 (32·9--162·9)−53·2Food-borne trematodiases2034·5 (349·5--8097·9)1529·2 (406·1--4437·5)−7·9180·0 (31·3--709·9)108·5 (28·8--316·7)−27·2Other neglected tropical diseases1028·3 (556·3--2492·1)508·1 (284·8--1046·0)−47·588·1 (47·5--214·3)41·2 (24·4--76·9)−48·8**Maternal disorders**1401·2 (1061·6--2050·8)545·9 (317·4--1266·9)−64·9111·6 (83·0--169·6)37·4 (22·3--83·2)−69·4Maternal haemorrhage319·3 (247·7--439·2)95·2 (69·7--119·6)−69·925·2 (19·6--34·6)6·8 (4·9--8·5)−72·9Maternal sepsis174·6 (133·9--241·6)41·5 (30·5--54·2)−76·013·2 (10·2--18·4)3·0 (2·2--3·9)−77·2Hypertensive disorders of pregnancy159·7 (124·9--215·5)46·6 (34·1--64·3)−70·912·2 (9·6--16·4)3·4 (2·5--4·7)−72·3Obstructed labour155·3 (28·2--568·3)196·3 (23·1--790·5)25·014·7 (2·5--54·3)12·6 (1·6--50·8)−12·8Abortion204·3 (159·2--280·4)55·3 (39·2--79·2)−73·015·7 (12·3--21·7)3·9 (2·8--5·7)−75·0Other maternal disorders388·0 (296·4--539·3)111·1 (69·9--225·9)−73·530·6 (23·4--43·5)7·7 (4·9--15·0)−76·4**Neonatal disorders**31 212·8(26 661·0--35 682·6)8678·8(6681·0--10 384·2)−72·32418·1(2066·0--2763·7)926·8(706·3--1117·6)−61·9Preterm birth complications8804·0 (6344·9--11 790·5)2858·1 (2187·8--3742·5)−67·3683·1 (494·2--913·6)304·6 (230·1--403·0)−55·1Neonatal encephalopathy (birth asphyxia/birth trauma)10 569·3 (7655·4--14 118·2)3255·8 (2338·5--4438·7)−69·0823·4 (598·2--1097·9)333·6 (231·9--465·3)−59·2Sepsis and other infectious disorders of the newborn baby436·9 (165·5--962·7)139·8 (69·7--271·6)−65·833·7 (12·8--74·3)15·8 (7·9--30·7)−49·9Other neonatal disorders11 402·6 (6837·5--16 172·4)2425·2 (1622·1--3505·8)−78·9878·0 (525·7--1245·8)272·8 (182·0--394·7)−69·1**Nutritional deficiencies**5513·7 (4040·5--7469·5)3307·5 (2350·5--4613·3)−39·4445·9 (328·2--600·8)305·9 (216·7--428·4)−30·8Protein-energy malnutrition1013·8 (804·4--1385·8)321·2 (231·1--406·1)−68·182·5 (66·7--112·0)30·1 (21·3--39·2)−63·3Iodine deficiency322·7 (207·8--490·4)300·9 (183·8--480·3)−7·227·9 (17·8--42·3)21·3 (13·1--34·0)−23·8Vitamin A deficiency117·9 (86·6--154·0)63·4 (44·3--86·8)−46·19·4 (6·9--12·3)5·2 (3·7--7·1)−44·8Iron-deficiency anemia4000·3 (2679·3--5881·1)2588·9 (1693·2--3834·7)−35·2320·8 (215·5--472·1)246·8 (162·5--363·5)−23·1Other nutritional deficiencies59·0 (49·5--76·6)33·2 (22·0--40·0)−42·75·3 (4·5--6·7)2·6 (1·7--3·1)−51·0**Other communicable, maternal, neonatal, and nutritional disorders**4422·9 (3724·9--5283·1)3107·2 (2579·9--3591·2)−29·0377·0 (322·5--444·2)244·7 (197·3--285·9)−34·5Sexually transmitted diseases excluding HIV1631·0 (1059·3--2349·6)510·6 (302·4--812·9)−69·2130·3 (85·2--189·0)42·3 (25·7--66·2)−68·0Syphilis1241·4 (766·4--1910·3)183·6 (101·2--310·0)−85·398·8 (62·0--150·5)18·8 (10·0--32·6)−81·3Sexually transmitted chlamydial diseases231·2 (97·1--427·4)220·9 (81·4--438·9)−5·917·9 (7·7--32·8)16·1 (5·9--31·9)−11·6Gonococcal infection50·3 (25·9--83·5)43·9 (18·9--82·2)−14·14·2 (2·2--7·0)3·1 (1·3--5·8)−28·3Trichomoniasis33·0 (0·2--99·6)24·8 (0·1--77·4)−25·12·6 (0·0--7·6)1·8 (0·0--5·6)−30·0Other sexually transmitted diseases75·1 (35·4--117·4)37·4 (20·8--65·6)−51·86·7 (3·1--10·5)2·5 (1·4--4·5)−63·5Hepatitis1480·7 (1323·3--1673·3)1442·8 (1221·6--1714·3)−3·2138·3 (124·0--155·5)97·8 (82·9--116·1)−29·8Acute hepatitis A308·5 (147·7--703·3)179·1 (76·0--539·5)−44·628·9 (13·7--66·3)12·8 (5·7--37·5)−56·4Acute hepatitis B864·6 (636·5--1100·3)1083·7 (739·2--1394·0)25·884·8 (63·8--108·4)71·7 (49·5--91·9)−14·8Acute hepatitis C25·9 (15·2--41·4)41·8 (28·3--57·1)66·02·6 (1·6--4·2)2·8 (1·9--3·8)8·1Acute hepatitis E281·7 (160·9--461·6)138·2 (71·0--240·2)−51·621·9 (12·6--35·9)10·5 (5·5--18·0)−53·0Leprosy0·3 (0·1--0·8)\<0·05 (0·0--0·2)−85·1\<0·05 (0·0--0·1)\<0·05 (0·0--0·05)−88·3Other infectious diseases1311·0 (1047·1--1870·7)1153·8 (711·7--1417·5)−5·9108·5 (88·2--151·5)104·7 (64·0--130·1)3·1**Non-communicable diseases217 135·5 (202 900·7--234 686·3)243 787·7 (224 298·4--264 558·7)12·322 358·9 (20 943·7--24 144·9)17 021·8 (15 673·6--18 458·5)--23·8Neoplasms**42 123·6(38 081·6--47 195·5)53 105·5(48 351·7--58 136·7)26·34471·5(4041·5--5040·1)3579·6(3257·3--3908·9)−19·8Oesophageal cancer3868·4 (3168·4--5255·7)3858·1 (2534·0--4960·1)4·9437·5 (357·9--593·1)258·8 (170·7--334·5)−37·9Stomach cancer7440·6 (5626·0--10 084·2)6615·6 (4806·1--8739·3)−11·1819·7 (621·2--1109·4)444·8 (323·8--584·2)−45·8Liver cancer7370·7 (6070·8--8874·6)10 088·6 (8790·2--13 301·8)35·0784·3 (653·3--935·5)659·7 (574·1--866·3)−16·9Liver cancer secondary to hepatitis B3944·8 (3240·8--4694·3)5464·1 (4654·1--7228·2)36·5421·2 (344·7--500·7)357·1 (304·1--467·1)−16·2Liver cancer secondary to hepatitis C1094·2 (907·5--1303·4)1693·8 (1419·4--2194·8)53·7122·5 (101·4--146·1)112·3 (94·3--144·0)−8·8Liver cancer secondary to alcohol use1404·6 (1128·7--1680·3)1892·6 (1564·1--2514·5)32·8149·1 (120·0--177·2)122·9 (101·5--162·6)−18·6Other liver cancer927·0 (755·7--1166·9)1038·0 (836·5--1413·1)9·891·5 (74·5--112·2)67·5 (54·3--92·7)−27·9Larynx cancer236·8 (108·3--441·7)311·2 (136·0--571·1)30·126·8 (12·3--50·4)20·8 (9·1--38·3)−23·2Trachea, bronchus, and lung cancers6305·9 (5233·5--8931·3)11 318·4 (7921·4--13 281·6)88·0702·8 (582·5--996·2)760·4 (529·6--890·0)13·5Breast cancer954·6 (903·0--1001·7)1670·7 (1499·1--1912·8)73·7101·9 (96·6--106·8)107·0 (96·3--122·3)4·1Cervical cancer557·4 (374·8--868·3)742·0 (331·3--984·4)51·460·6 (40·6--94·0)48·0 (21·7--63·1)−10·8Uterine cancer154·1 (103·9--325·1)287·0 (106·1--380·5)127·016·5 (11·3--35·0)18·8 (7·0--24·7)38·7Prostate cancer69·7 (44·1--118·7)178·4 (80·5--264·4)115·98·0 (5·1--13·5)12·9 (5·8--19·1)37·0Colon and rectum cancers2447·4 (1966·7--2710·3)3422·6 (3003·7--4487·9)35·9263·8 (213·7--292·0)230·7 (203·2--300·8)−14·9Mouth cancer205·2 (169·5--234·5)360·7 (262·5--469·6)76·122·1 (18·3--25·2)23·9 (17·5--31·0)8·2Nasopharynx cancer739·8 (505·1--1063·6)1059·7 (644·8--1540·3)39·376·7 (53·1--111·7)68·8 (42·5--98·2)−13·0Cancer of other part of pharynx and oropharynx120·6 (75·5--164·7)144·2 (99·1--227·6)18·312·7 (7·9--17·1)9·6 (6·6--15·2)−25·0Gallbladder and biliary tract cancer415·6 (289·7--643·7)644·2 (417·1--934·4)56·245·3 (31·9--70·1)43·9 (28·3--63·7)−2·7Pancreatic cancer767·0 (585·1--1016·7)1321·8 (998·7--1698·2)74·184·9 (65·1--112·4)88·5 (66·7--113·2)5·3Malignant melanoma of skin79·3 (41·7--97·2)155·8 (109·5--278·8)82·38·0 (4·3--9·9)10·6 (7·4--18·9)21·9Non-melanoma skin cancer76·1 (40·5--131·5)96·1 (56·8--161·0)24·88·4 (4·4--14·7)6·6 (3·9--11·1)−22·1Ovarian cancer457·6 (312·0--591·8)602·9 (399·9--850·1)21·947·9 (32·6--61·6)39·3 (26·2--55·4)−24·2Testicular cancer39·1 (19·9--55·7)29·4 (15·7--53·5)−30·63·6 (1·8--5·1)2·0 (1·1--3·7)−48·4Kidney and other urinary organ cancers425·6 (292·4--595·7)836·6 (587·4--1096·6)97·743·1 (30·2--59·9)57·7 (40·4--75·9)34·5Bladder cancer296·4 (242·4--368·9)411·1 (320·1--510·0)39·333·6 (27·6--42·1)28·6 (22·3--35·4)−14·3Brain and nervous system cancers1256·5 (806·0--1674·0)1496·5 (912·7--2075·0)19·9125·3 (81·2--169·0)102·3 (61·7--142·7)−17·9Thyroid cancer136·9 (106·3--184·2)212·6 (148·5--282·8)56·714·3 (11·1--19·2)14·3 (10·0--18·9)0·7Hodgkin\'s disease64·7 (42·7--98·6)41·4 (25·9--61·9)−36·45·8 (3·9--8·9)3·1 (1·9--4·8)−48·1Non-Hodgkin lymphoma738·5 (624·8--860·0)812·2 (649·9--982·0)8·970·6 (59·7--81·9)57·6 (45·9--70·1)−19·0Multiple myeloma157·5 (104·8--235·0)250·1 (146·6--363·8)59·615·5 (10·4--23·1)17·0 (10·0--24·8)10·8Leukaemia2772·1 (2166·2--3533·1)2418·1 (1856·4--2975·7)−9·5235·0 (184·5--298·9)184·2 (141·0--226·4)−18·7Other neoplasms3969·6 (2815·5--4898·8)3719·4 (2707·8--4860·7)−7·7396·8 (277·6--487·5)259·7 (189·7--335·5)−35·5**Cardiovascular and circulatory diseases**45 267·9(42 851·2--51 606·5)58 205·5(53 245·8--61 100·3)30·65114·5(4842·2--5826·4)4065·1(3707·6--4264·6)−19·3Rheumatic heart disease4140·4 (3766·9--4548·5)1486·6 (1306·6--1691·0)−64·1420·7 (382·5--462·8)101·6 (89·3--115·9)−75·8Ischaemic heart disease10 127·0(9193·6--12 758·3)17 885·8(15 135·4--19 306·6)83·01139·8(1036·0--1434·6)1242·5(1053·5--1339·7)13·1Cerebrovascular disease24 876·8(22 724·2--30 679·9)30 138·9(25 523·4--32 406·0)28·92894·6(2651·5--3550·7)2101·5(1783·9--2257·2)−23·0Ischaemic stroke6252·0 (4408·0--9652·9)8383·8 (6523·0--11 529·4)35·9767·5 (547·0--1169·1)612·4 (478·1--835·8)−19·1Haemorrhagic and other non-ischaemic stroke18 624·7(13 636·3--23 424·5)21 755·1(17 436·2--25 934·6)16·82127·0(1557·1--2669·7)1489·1(1192·7--1781·1)−30·0Hypertensive heart disease2307·1 (1866·1--2994·8)2767·4 (2169·8--3284·5)22·8271·2 (218·8--351·2)194·7 (152·4--230·9)−26·6Cardiomyopathy and myocarditis1139·2 (619·8--1796·4)1012·6 (683·4--1380·0)−8·5107·8 (61·2--166·2)74·5 (49·5--102·4)−29·1Atrial fibrillation and flutter337·3 (232·9--465·3)596·2 (425·6--809·7)76·939·9 (27·6--55·4)42·6 (30·3--58·0)6·7Aortic aneurysm692·1 (243·1--1208·2)1010·1 (563·5--1569·9)45·578·7 (27·8--136·2)70·4 (39·1--109·7)−10·8Peripheral vascular disease81·7 (46·3--126·5)181·5 (110·9--279·6)120·910·0 (5·7--15·7)13·0 (7·9--20·2)29·2Endocarditis397·0 (268·7--545·9)386·7 (275·0--507·2)−2·036·1 (25·2--48·8)27·2 (19·7--35·5)−24·2Other cardiovascular and circulatory diseases1169·3 (813·0--1678·6)2739·7 (2367·5--3187·2)137·1115·8 (83·3--162·2)197·1 (169·4--230·3)72·5**Chronic respiratory diseases**29 139·1(27 286·2--31 283·1)19 898·2(17 579·2--23 062·4)−32·13336·8(3142·6--3562·9)1425·5(1264·5--1642·1)−57·5Chronic obstructive pulmonary disease26 470·3(24 344·5--28 530·7)16 723·8(14 413·7--19 402·9)−36·83074·8(2833·2--3295·2)1190·6(1033·8--1373·3)−61·3Pneumoconiosis169·4 (104·6--290·6)153·4 (65·0--365·6)−21·019·2 (11·8--33·1)10·7 (4·5--26·0)−51·2Asthma1238·0 (898·2--1713·5)1094·9 (781·9--1503·2)−11·9119·2 (88·0--160·8)83·6 (58·7--115·9)−30·0Interstitial lung disease and pulmonary sarcoidosis144·9 (79·4--254·4)199·1 (122·3--290·0)41·915·1 (8·5--25·4)14·2 (8·6--20·9)−5·0Other chronic respiratory diseases1116·5 (892·3--1378·7)1727·0 (1192·8--2198·4)57·7108·6 (86·5--134·8)126·4 (87·2--160·0)18·6**Cirrhosis of the liver**5403·9 (3935·6--6147·2)3316·1 (2613·4--5377·2)−48·7567·4 (416·2--645·6)217·1 (171·5--352·5)−68·0Cirrhosis of the liver secondary to hepatitis B2282·4 (1619·0--2720·9)1447·3 (1103·7--2362·8)−46·1244·7 (173·3--291·3)94·8 (72·4--154·7)−67·1Cirrhosis of the liver secondary to hepatitis C1035·7 (728·1--1210·3)647·1 (499·2--1061·8)−46·6112·7 (79·2--131·6)42·6 (32·9--69·5)−67·7Cirrhosis of the liver secondary to alcohol use1173·7 (801·0--1427·9)784·1 (583·3--1330·7)−43·4122·9 (83·3--149·5)50·6 (37·8--85·9)−65·2Other cirrhosis of the liver912·1 (634·2--1101·4)437·6 (322·6--734·8)−59·787·2 (61·2--105·0)29·1 (21·6--48·8)−71·9**Digestive diseases (except cirrhosis)**5435·6 (4637·1--6243·7)3869·5 (3298·6--4664·5)−29·2540·0 (464·3--614·9)273·3 (232·9--327·9)−49·7Peptic ulcer disease1411·5 (1069·1--1646·3)453·1 (372·3--594·1)−68·5150·5 (114·0--173·5)31·0 (25·5--40·7)−79·7Gastritis and duodenitis296·9 (148·5--562·3)229·0 (101·6--520·0)−25·826·5 (13·6--49·1)15·6 (7·1--35·3)−43·3Appendicitis231·5 (149·5--328·0)63·7 (38·8--104·9)−73·521·2 (13·5--29·5)4·8 (2·9--7·9)−78·1Paralytic ileus and intestinal obstruction without hernia619·0 (304·7--873·0)241·9 (161·6--439·4)−70·556·4 (29·3--76·9)17·9 (11·8--32·6)−76·2Inguinal or femoral hernia115·4 (57·7--270·1)113·5 (41·7--286·5)−5·211·6 (6·1--26·0)8·4 (3·1--21·1)−31·3Non-infective inflammatory bowel disease413·0 (225·2--720·5)377·8 (209·7--687·2)−9·336·3 (20·3--63·7)27·9 (15·4--50·4)−23·8Vascular disorders of intestine120·4 (35·0--362·3)174·2 (63·2--471·4)55·113·4 (4·0--39·9)12·4 (4·5--33·2)−0·3Gall bladder and bile duct disease476·7 (361·8--618·6)448·2 (330·9--573·5)−6·048·3 (36·6--61·4)31·3 (22·8--40·4)−35·4Pancreatitis177·8 (99·6--270·1)204·5 (141·1--287·9)15·618·7 (10·5--28·3)13·8 (9·6--19·1)−26·0Other digestive diseases1573·5 (1106·9--1887·9)1563·6 (1240·6--2215·8)−4·7157·1 (110·1--189·0)110·2 (87·2--156·0)−32·7**Neurological disorders**5482·5 (4638·7--6496·5)6711·1 (5681·0--7763·9)22·0515·6 (442·1--602·5)481·5 (409·0--553·7)−7·1Alzheimer\'s disease and other dementias957·3 (732·6--1179·8)1592·9 (1261·6--2015·3)62·4116·1 (89·7--142·8)118·4 (93·3--149·5)0·2Parkinson\'s disease173·8 (117·6--230·5)265·1 (195·9--371·1)47·419·5 (13·6--26·1)18·7 (13·8--26·1)−7·3Epilepsy1723·1 (1354·1--2040·6)1507·4 (1261·8--1805·5)−13·2145·9 (115·5--171·0)111·7 (93·2--134·5)−24·2Multiple sclerosis174·4 (102·0--247·4)148·9 (105·9--199·1)−16·317·5 (10·0--24·9)9·7 (6·9--12·9)−45·4Migraine1781·7 (1203·1--2480·3)2293·4 (1504·3--3185·7)29·0155·4 (104·8--216·6)157·9 (103·5--219·3)1·7Tension-type headache285·1 (170·6--446·3)375·0 (225·1--589·9)31·625·8 (15·4--40·4)25·7 (15·4--40·3)−0·3Other neurological disorders387·1 (228·2--1032·1)528·4 (374·6--859·9)51·035·5 (22·1--87·9)39·4 (27·1--66·9)19·6**Mental and behavioural disorders**24 450·5(20 025·4--29 182·9)29 954·1(24 451·7--35 839·5)22·72173·9(1779·6--2591·3)2091·6(1708·3--2502·6)−3·8Schizophrenia2554·2 (1756·7--3396·2)3472·3 (2307·5--4719·6)35·6250·8 (172·5--333·4)225·5 (150·1--305·9)−10·4Alcohol use disorders2801·0 (1814·0--4208·7)3489·3 (2219·0--5163·9)25·2245·9 (159·3--370·4)236·6 (150·5--349·9)−3·6Drug use disorders2073·4 (1368·7--2961·2)2369·2 (1536·5--3534·6)13·5166·5 (110·3--237·5)168·6 (109·3--250·5)0·9Opioid use disorders880·2 (456·7--1544·8)1034·7 (533·3--1767·4)18·072·1 (37·4--126·5)72·9 (37·7--124·2)1·6Cocaine use disorders38·7 (20·5--65·9)36·8 (16·5--67·4)−8·03·2 (1·7--5·4)2·6 (1·2--4·7)−20·4Amphetamine use disorders342·1 (167·8--601·2)389·5 (192·1--684·3)14·027·7 (13·5--48·2)27·5 (13·5--48·3)0·0Cannabis use disorders353·9 (169·4--637·1)367·5 (177·3--686·7)3·326·4 (12·6--47·6)26·5 (12·8--49·5)0·2Other drug use disorders458·4 (263·0--732·9)540·7 (328·1--861·5)15·937·2 (21·2--59·4)39·0 (23·6--62·0)3·0Unipolar depressive disorders9470·7 (6727·6--12 275·5)11 767·3 (8485·4--15 358·2)24·3858·5 (608·4--1112·8)818·3 (591·4--1069·2)−4·5Major depressive disorder7633·8 (5302·1--10 095·7)9318·1 (6511·2--12 393·1)22·0690·3 (479·7--915·9)649·8 (453·8--864·0)−5·8Dysthymia1836·9 (1193·2--2565·0)2449·2 (1604·8--3381·2)33·4168·2 (109·6--234·1)168·6 (110·3--233·4)0·2Bipolar affective disorder2192·2 (1352·7--3238·7)2758·5 (1700·3--4021·4)26·0193·7 (119·6--286·3)185·8 (114·9--270·9)−3·9Anxiety disorders2302·7 (1566·4--3227·2)2885·0 (1914·7--4132·3)24·8201·8 (137·5--281·6)202·4 (134·6--289·0)−0·1Eating disorders156·1 (82·7--234·3)234·8 (144·2--357·4)51·312·9 (6·9--19·3)16·6 (10·3--25·3)28·5Pervasive development disorders1331·0 (898·0--1880·3)1570·3 (1048·7--2258·6)18·2114·9 (77·5--162·2)117·3 (77·9--168·8)2·2Autism700·2 (455·4--1037·3)831·9 (521·2--1212·7)18·860·4 (39·3--89·0)62·3 (39·1--90·7)3·1Asperger\'s syndrome630·8 (404·1--938·4)738·4 (483·0--1095·2)16·654·5 (35·0--80·7)55·0 (35·9--81·5)0·6Childhood behavioural disorders1146·9 (664·9--1833·9)1054·6 (625·7--1617·9)−7·791·6 (52·8--146·6)94·3 (56·0--144·7)3·1Attention-deficit hyperactivity disorder105·5 (60·2--166·4)99·5 (55·4--156·4)−5·98·3 (4·7--13·0)8·3 (4·6--13·1)0·2Conduct disorder1041·4 (580·3--1716·3)955·2 (548·7--1503·9)−8·083·3 (46·3--137·5)86·0 (49·4--136·1)3·4Idiopathic intellectual disability181·7 (86·9--300·3)126·4 (51·0--232·3)−30·114·8 (7·0--24·8)9·6 (3·8--17·4)−35·3Other mental and behavioural disorders240·6 (132·5--350·9)226·4 (146·9--341·3)−13·822·4 (12·4--32·7)16·6 (10·9--25·0)−32·1**Diabetes, urogenital, blood, and endocrine diseases**13 110·6(10 822·3--16 111·4)16 976·7(14 276·6--20 599·6)30·71291·3(1066·6--1582·5)1186·5(998·3--1439·8)−7·3Diabetes mellitus4845·8 (3822·2--6253·6)7834·7 (6342·2--9799·0)63·4512·6 (402·2--665·7)531·8 (431·6--664·0)5·1Acute glomerulonephritis636·5 (64·8--2360·9)87·3 (32·8--198·1)−80·158·4 (5·9--219·4)6·4 (2·4--14·3)−83·8Chronic kidney diseases2085·3 (1827·2--2789·1)2781·6 (2381·3--3118·3)39·7210·9 (185·3--279·9)191·0 (163·5--214·6)−5·1Chronic kidney disease due to diabetes mellitus304·2 (251·9--404·5)471·7 (389·1--550·4)60·933·4 (27·6--44·2)31·5 (26·1--36·8)−2·0Chronic kidney disease due to hypertension383·0 (327·6--515·4)530·8 (447·8--607·2)44·439·7 (34·0--52·5)36·2 (30·4--41·4)−5·2Chronic kidney disease unspecified1398·2 (1215·6--1894·5)1779·1 (1521·4--2016·5)33·5137·8 (119·6--183·6)123·2 (105·4--139·6)−6·2Urinary diseases and male infertility1292·4 (906·2--1774·1)1767·2 (1191·9--2561·3)35·4139·0 (97·2--192·1)120·7 (82·1--174·4)−14·0Tubulointerstitial nephritis, pyelonephritis, and urinary tract infections303·8 (177·9--469·5)240·5 (183·9--335·3)−21·228·1 (16·7--41·7)18·0 (13·8--24·9)−36·4Urolithiasis215·6 (124·0--392·7)197·4 (122·5--313·8)−5·923·0 (13·1--41·9)13·3 (8·3--21·1)−40·5Benign prostatic hyperplasia701·7 (438·0--1079·4)1252·5 (772·5--1981·4)78·480·9 (50·6--124·4)84·3 (52·1--133·2)4·2Male infertility28·1 (9·4--67·2)37·2 (13·0--88·2)32·12·5 (0·8--5·9)2·4 (0·8--5·5)−4·5Other urinary diseases43·2 (27·1--56·3)39·5 (29·6--57·4)−13·54·6 (2·8--5·9)2·8 (2·1--4·0)−42·5Gynaecological diseases1575·7 (988·5--2500·9)1844·2 (1109·5--3063·5)16·2138·4 (87·5--218·8)124·4 (74·7--204·7)−10·8Uterine fibroids339·9 (208·3--544·5)451·2 (240·2--791·3)30·633·2 (19·6--54·1)28·4 (15·2--49·5)−15·5Polycystic ovarian syndrome452·1 (214·5--861·1)535·5 (252·3--1012·5)18·337·3 (17·7--70·9)36·7 (17·2--69·6)−1·7Female infertility20·0 (6·9--46·6)27·5 (9·9--64·6)37·01·8 (0·6--4·1)1·7 (0·6--4·1)−1·1Endometriosis95·4 (33·6--181·6)116·1 (40·1--235·4)21·67·9 (2·8--15·0)8·1 (2·8--16·4)3·1Genital prolapse262·7 (103·7--583·9)383·7 (145·4--822·0)46·725·3 (10·1--55·5)25·3 (9·6--54·3)0·3Premenstrual syndrome255·8 (0·0--682·6)250·3 (0·0--656·6)−2·719·7 (0·0--52·7)18·7 (0·0--49·1)−5·2Other gynaecological diseases149·7 (108·4--204·4)79·8 (58·0--111·7)−46·813·3 (9·8--18·3)5·4 (3·9--7·4)−59·6Haemoglobinopathies and haemolytic anaemias1858·0 (1191·7--2755·5)1512·5 (1106·9--2063·0)−17·1159·0 (102·6--235·2)122·3 (89·5--167·8)−21·7Thalassaemias1255·6 (910·9--1752·0)1152·2 (824·3--1619·9)−7·3105·2 (76·1--146·1)91·6 (65·7--127·6)−11·9Sickle cell disorders28·0 (18·0--42·8)37·4 (22·2--59·9)33·32·4 (1·5--3·7)3·3 (1·9--5·4)37·5G6PD deficiency50·4 (30·7--91·8)36·4 (27·2--48·4)−22·94·3 (2·7--7·7)2·9 (2·2--4·0)−27·6Other haemoglobinopathies and haemolytic anaemias523·9 (239·4--1149·3)286·6 (157·4--480·8)−38·547·0 (21·5--100·3)24·5 (13·8--42·2)−42·0Other endocrine, nutritional, blood, and immune disorders816·9 (609·5--1093·4)1149·3 (839·3--1606·3)40·873·0 (55·3--99·1)89·9 (64·1--126·7)23·7**Musculoskeletal disorders**22 450·5(17 056·0--28 497·3)32 746·0(25 008·9--40 768·0)45·72205·4(1690·1--2780·6)2216·8(1690·7--2758·4)0·5Rheumatoid arthritis595·6 (440·8--756·9)791·5 (601·7--1013·2)31·461·3 (45·6--77·4)53·8 (40·9--68·9)−13·0Osteoarthritis2393·7 (1556·3--3516·5)4164·5 (2778·2--6066·1)73·2273·3 (177·7--401·9)272·0 (181·6--395·7)−0·9Low back and neck pain15 419·9(10 644·3--21 027·7)21 939·0(15 213·0--29 528·8)42·41478·6(1023·0--2010·8)1494·1(1036·4--2009·4)1·1Low back pain10 523·5 (7159·4--14 513·5)15 131·8 (10 278·6--20 522·3)43·91019·5 (696·8--1403·7)1028·5 (699·1--1396·1)0·9Neck pain4896·4 (3404·7--6729·8)6807·2 (4772·2--9378·6)39·1459·1 (318·8--630·2)465·6 (326·9--641·1)1·6Gout12·4 (7·6--18·2)20·5 (12·6--30·4)65·61·4 (0·8--2·0)1·4 (0·8--2·0)−0·4Other musculoskeletal disorders4028·8 (3306·4--4604·7)5830·4 (4828·6--6636·4)44·6390·9 (322·5--447·1)395·6 (327·9--449·6)1·1**Other non-communicable diseases**24 271·1(19 351·4--31 778·1)19 005·1(13 581·9--27 514·6)−22·02142·4(1684·7--2851·3)1484·7(1095·4--2093·1)−30·9Congenital anomalies11 234·4 (9294·0--15 172·2)4098·6 (3132·6--5655·8)−63·5865·0 (716·6--1166·8)414·1 (310·3--584·2)−52·1Neural tube defects2275·4 (1108·8--3887·1)427·8 (271·1--710·4)−81·0176·5 (86·3--300·6)41·2 (24·9--73·6)−76·8Congenital heart anomalies6040·9 (5191·6--7098·7)2508·9 (1975·0--3243·6)−58·4462·8 (398·7--542·3)258·9 (201·3--337·6)−44·0Cleft lip and cleft palate448·1 (177·9--1097·8)113·1 (68·9--186·2)−71·834·3 (13·8--83·5)10·9 (6·4--18·7)−64·8Down\'s syndrome242·1 (129·4--421·5)175·6 (123·8--245·8)−24·319·4 (10·6--33·2)14·2 (10·0--19·6)−23·9Other chromosomal abnormalities1000·8 (254·9--3085·3)296·0 (157·8--639·5)−63·677·3 (20·2--236·8)29·8 (15·1--68·0)−53·1Other congenital anomalies1227·2 (333·2--2834·7)577·1 (345·7--1160·4)−44·994·7 (26·5--216·8)59·1 (33·7--123·6)−28·4Skin and subcutaneous diseases5604·0 (3661·2--8513·9)5926·4 (3709·7--9185·6)5·2491·6 (321·5--745·8)442·0 (275·6--684·5)−10·5Eczema1053·2 (532·6--1694·8)1192·6 (592·9--1943·4)13·391·1 (46·2--146·1)91·3 (45·3--149·0)0·5Psoriasis168·5 (79·3--285·0)239·4 (110·6--407·4)42·716·3 (7·7--27·6)16·3 (7·6--27·6)0·1Cellulitis220·7 (131·7--387·8)106·6 (48·9--301·0)−59·119·4 (11·7--34·4)8·0 (3·7--22·7)−65·1Abscess, impetigo, and other bacterial skin diseases478·5 (316·1--688·1)259·8 (144·0--484·9)−47·140·3 (26·7--58·1)21·0 (11·5--38·9)−49·3Scabies350·7 (158·3--700·7)256·1 (116·2--497·8)−26·630·0 (13·6--60·1)19·8 (9·0--38·4)−33·4Fungal skin diseases273·5 (85·1--635·9)355·2 (113·4--837·3)29·825·4 (7·9--59·2)25·8 (8·2--60·5)1·3Viral skin diseases498·3 (189·4--895·9)509·2 (196·9--913·7)3·141·9 (15·9--75·2)41·0 (15·8--73·9)−1·6Acne vulgaris819·3 (372·3--1536·1)794·7 (362·1--1527·6)−3·261·6 (28·0--115·3)61·8 (28·1--119·0)0·0Alopecia areata206·3 (60·2--419·8)252·1 (70·3--538·2)22·518·4 (5·4--37·3)18·0 (5·0--38·4)−1·8Pruritus261·9 (114·1--491·9)375·5 (171·0--751·3)42·425·7 (11·2--47·9)25·6 (11·7--51·2)−0·8Urticaria432·1 (177·6--756·1)523·3 (209·4--932·8)20·438·4 (15·7--66·7)38·3 (15·3--68·1)−0·8Decubitus ulcer155·6 (103·8--248·1)136·7 (75·0--256·4)−15·016·6 (10·9--27·0)9·8 (5·4--18·2)−42·5Other skin and subcutaneous diseases685·4 (318·1--1295·3)925·1 (438·7--1750·2)35·166·6 (30·8--126·0)65·2 (30·9--123·3)−2·0Sense organ diseases4802·5 (3355·8--6779·3)5906·2 (4136·2--8413·2)22·9527·4 (369·2--736·6)412·5 (289·3--586·9)−21·8Glaucoma101·0 (71·6--139·4)157·7 (113·9--213·2)57·011·7 (8·3--16·3)11·0 (7·9--14·9)−6·2Cataracts646·2 (492·0--831·6)504·8 (380·9--653·5)−21·974·5 (56·7--95·8)35·1 (26·4--45·3)−53·0Macular degeneration205·9 (148·4--276·7)431·3 (324·9--556·0)109·925·6 (18·5--34·3)31·5 (23·8--40·6)23·6Refraction and accommodation disorders564·9 (425·6--743·0)767·1 (571·1--1005·7)35·863·3 (47·8--83·2)54·3 (40·5--71·0)−14·3Other hearing loss2715·1 (1597·2--4262·8)3151·4 (1849·7--5120·5)15·5292·6 (173·7--455·2)219·6 (129·1--355·3)−25·1Other vision loss548·0 (252·0--1014·6)866·7 (403·3--1642·5)58·357·7 (26·5--106·9)59·1 (27·5--112·0)2·4Other sense organ diseases21·4 (7·3--50·2)27·3 (9·3--61·0)27·42·0 (0·7--4·7)2·0 (0·7--4·5)0·3Oral disorders2299·9 (1224·0--4066·9)2934·1 (1468·5--5368·6)26·5233·2 (127·1--406·9)200·5 (100·4--364·6)−14·8Dental caries886·6 (348·4--1759·8)1056·9 (437·7--2040·2)18·977·4 (30·6--152·6)77·0 (31·8--149·2)−0·8Periodontal disease745·0 (285·5--1593·9)1231·5 (460·3--2676·4)65·278·9 (30·2--168·4)79·5 (29·7--172·8)0·7Edentulism668·3 (386·0--1048·1)645·8 (376·2--1013·0)−3·376·9 (44·5--120·6)44·0 (25·7--69·2)−42·7Sudden infant death syndrome330·3 (67·8--1297·6)139·9 (47·0--370·1)−49·625·1 (5·2--98·7)15·5 (5·2--41·0)−26·8**Injuries51 189·9(44 186·7--57 117·4)40 804·0(35 982·2--48 950·1)--22·34371·5(3798·2--4872·8)2939·9(2596·8--3515·1)--34·3Transport injuries**10 583·2 (7969·0--15 143·4)15 726·6 (11 842·4--21 218·3)50·3921·4 (694·4--1306·4)1103·2 (828·2--1494·9)20·7Road injury10 017·3 (7555·8--13 977·9)14 962·3 (11 418·0--19 995·4)55·6870·8 (654·8--1209·0)1050·3 (800·7--1403·5)25·2Pedestrian injury by road vehicle2257·3 (1318·3--3423·7)5595·6 (4267·2--7256·6)139·6197·5 (116·2--299·5)389·8 (296·4--502·3)90·8Pedal cycle vehicle391·7 (242·1--614·6)451·4 (283·6--615·0)16·334·0 (21·5--51·9)32·4 (20·4--43·8)−4·3Motorised vehicle with two wheels2182·7 (1381·6--3179·7)2646·2 (2093·6--3353·9)22·9189·0 (122·1--272·4)184·5 (146·5--233·5)−1·8Motorised vehicle with three or more wheels2264·6 (1542·0--3013·1)4004·5 (3158·4--4940·2)73·4196·4 (135·0--260·7)280·3 (220·3--348·0)40·8Road injury other3088·8 (1196·6--6449·1)2464·4 (924·6--5589·7)−22·3269·6 (105·9--557·3)177·0 (66·4--399·0)−36·4Other transport injury565·9 (406·7--770·7)764·3 (542·4--1037·1)34·750·6 (36·5--68·3)52·9 (37·4--71·7)4·1**Unintentional injuries other than transport injuries**29 833·2(25 958·0--33 260·9)17 783·1(15 550·7--20 527·2)−40·82516·9(2214·1--2805·9)1334·5(1174·5--1541·1)−47·4Falls5752·0 (4694·8--7259·2)7058·3 (5624·8--8834·5)24·3567·7 (462·1--720·7)494·4 (394·5--613·6)−11·9Drowning10 212·4 (7166·0--12 426·4)3663·4 (3008·1--5370·1)−66·0802·5 (572·7--967·1)315·6 (254·2--484·9)−62·9Fire, heat, and hot substances892·0 (700·7--1132·8)582·7 (442·2--826·8)−35·877·4 (61·3--98·1)42·8 (32·5--61·9)−45·9Poisonings2686·9 (1996·5--4710·1)1613·7 (885·2--2123·1)−27·3230·5 (172·0--406·7)114·1 (63·7--150·3)−40·0Exposure to mechanical forces1792·8 (1348·8--2453·6)1130·0 (739·9--1436·6)−34·8152·3 (116·6--209·4)77·9 (51·4--99·1)−47·1Mechanical forces (firearm)677·4 (334·9--1134·0)208·2 (113·8--355·7)−69·256·9 (28·7--92·7)14·6 (8·0--24·9)−74·2Mechanical forces (other)1149·5 (607·8--2098·5)975·6 (530·3--1450·2)−11·698·5 (52·5--181·4)66·9 (37·0--99·0)−28·9Adverse effects of medical treatment287·9 (141·7--475·1)370·0 (255·7--519·0)32·225·6 (13·6--40·3)27·6 (18·4--39·0)10·3Animal contact474·6 (237·5--836·1)156·0 (92·9--246·4)−66·241·5 (20·8--71·5)11·7 (7·0--18·2)−71·1Animal contact (venomous)215·9 (99·1--495·7)71·9 (40·2--123·5)−63·419·4 (9·2--43·5)5·2 (2·9--9·1)−70·7Animal contact (non-venomous)258·7 (92·0--571·9)84·1 (46·3--148·6)−64·122·1 (8·1--47·2)6·4 (3·4--11·2)−68·4Unintentional injuries not classified elsewhere7734·6 (5740·5--9057·6)3209·0 (2493·5--3694·6)−58·8619·4 (464·8--720·1)250·4 (197·3--293·3)−59·9**Self-harm and interpersonal violence**10 773·5 (7173·7--12 847·8)7294·3 (5797·7--11 344·9)−42·3933·1 (627·3--1102·1)502·3 (401·7--780·4)−53·9Self-harm8959·3 (5433·1--10 915·0)5969·9 (4645·7--9717·0)−44·3785·0 (484·2--954·3)408·3 (318·3--664·1)−56·2Interpersonal violence1814·2 (1322·0--2249·4)1324·4 (1034·3--1987·4)−31·7148·2 (108·8--184·4)94·0 (73·3--141·2)−40·9Assault by firearm323·9 (165·9--625·7)150·4 (99·0--239·7)−51·527·2 (14·2--51·3)10·5 (6·9--16·9)−60·0Assault by sharp object484·5 (271·0--752·0)423·7 (290·1--621·4)−8·639·0 (22·4--59·9)29·5 (20·1--43·2)−21·5Assault by other means1030·9 (696·4--1403·7)789·4 (561·5--1069·5)−23·284·3 (58·0--113·3)56·6 (40·6--76·1)−32·6[^5]

[Appendix pp 7--8](#sec1){ref-type="sec"} ranks each country by the age-standardised DALY rate across the G20 for men and women in 2010. Men in China had higher than G20 average rates of DALYs caused by stroke, chronic obstructive pulmonary disease, liver cancer, stomach cancer, oesophageal cancer, and drowning. Chinese women had increased rates of DALYs caused by stroke, chronic obstructive pulmonary disease, road injury, self-harm, liver cancer, and stomach cancer. For some of the leading causes of disability, including low back pain and neck pain, China had rates that are indistinguishable from the G20 mean. Comparing 1990 (data not shown) with 2010, eight causes switched from significantly better than average to indistinguishable from average: falls, congenital anomalies, neonatal encephalopathy, poisonings, rheumatic heart disease, hookworm, ascariasis, and cysticercosis. For ischaemic heart disease, road injury and lung cancer (for which China was below the G20 average in 2010), rising rates mean that this situation might soon change.

[Figure 7](#fig7){ref-type="fig"} shows the percentage of DALYs attributable to major risk groups in 2010. The leading risk factor in China was a composite of dietary risk factors, accounting for 16·3% (14·5--18·0%) of DALYs and 30·6% (27·5--33·3%) of deaths. The composite diet risk factor is made up of 14 different components ([appendix p 8](#sec1){ref-type="sec"}). Analysed component by component, the most important factors in the dietary composite factor were diets that were low in fruits, high in sodium, or low in whole grains; all of which are problems with diet even in rural areas. The second leading risk factor was high blood pressure, which accounted for 12·0% (10·4--13·5) of DALYs and 24·6% (21·9--27·2) of deaths. The third major risk was tobacco, accounting for 9·5% (7·4--11·4) of DALYs and 16·4% (12·8--19·9) of deaths. Two sources of particulate matter (PM) 2·5 exposure, ambient air pollution and household air pollution, were the fourth and fifth leading risks, respectively. Total PM2·5 burden in China--the combination of ambient air pollution, household air pollution, and second-hand tobacco smoke---is very large. Four more risks or clusters of risks accounted for between 4% and 5·5% of DALYs: high fasting plasma glucose, alcohol use, occupational risks, high body-mass index, and physical inactivity. [Table 5](#tbl5){ref-type="table"} provides estimates for 1990 and 2010 of the attributable DALYs for 67 risk factors or clusters of risk factors. Compared with the G20 mean attributable DALY rates, China had significantly higher rates for ambient and household air pollution and low bone mineral density in 1990 and 2010. Dietary risks and high blood pressure worsened compared with the G20 average between 1990 and 2010 whereas occupational risks in 2010 were no longer distinguishable from the G20 average, but in 1990 were worse than the G20 average ([appendix p 9](#sec1){ref-type="sec"}). DALYs attributable to six risk factors increased in China from 1990 to 2010 by more than 40·0%: diet, high blood pressure, high fasting plasma glucose, high body-mass index, high cholesterol, and lead exposure. Four dietary factors each contributed more than 2·0% to total DALYs in 2010: low consumption of fruit, whole grain, and nuts and seeds and high intake of sodium. The burden of tobacco is also disaggregated into the burden from tobacco smoking (26·2 million DALYs \[95% UI 19·6--32·2\]) and from second-hand smoke exposure (3·8 million DALYs \[2·7--4·9\]).Figure 7Disability-adjusted life-years (DALYs) for both sexes in China in 2010Table 5Disability-adjusted life-years (in thousands) attributable to risk factors or risk factor clusters in China**DALYs (thousands) in male individualsDALYs (thousands) in female individualsDALYs (thousands) in both sexes**199020101990201019902010Unimproved water and sanitation976 (35--1911)139 (5--359)886 (32--1686)118 (4--303)1861 (67--3486)257 (9--663)Unimproved water source395 (15--957)53 (2--171)359 (14--864)44 (1--147)754 (29--1792)97 (3--319)Unimproved sanitation671 (17--1358)92 (2--263)609 (17--1199)78 (2--219)1279 (34--2525)170 (4--479)Air pollutionAmbient particulate matter pollution13 452 (11 054--15 846)16 068 (13 612--18 419)10 806 (8840--13 055)9160 (7767--10 570)24 258 (20 317--28 401)25 227 (21 771--28 595)Household air pollution from solid fuels21 923 (16 783--26 583)12 382 (8705--16 206)20 844 (17 619--23 989)8910 (6644--11 222)42 767 (35 924--48 879)21 292 (15 869--26 661)Ambient ozone pollution490 (150--920)400 (135--737)430 (134--802)250 (81--444)920 (284--1712)651 (220--1175)Other environmental risks437 (271--667)1930 (1131--3085)456 (251--657)1105 (679--1648)893 (608--1216)3035 (1943--4573)Residential radon..540 (52--1522)..222 (22--650)..762 (75--2092)Lead exposure437 (271--667)1389 (811--2134)456 (251--657)883 (538--1292)893 (608--1216)2273 (1550--3154)Child and maternal undernutrition10 206 (6303--14 355)1859 (1269--2612)10 530 (7376--14 390)2406 (1708--3297)20 736 (13 935--27 847)4264 (3066--5835)Suboptimal breastfeeding6067 (2456--9863)731 (279--1301)5045 (2064--8341)521 (198--883)11 113 (4498--17 488)1252 (488--2052)Non-exclusive breastfeeding5656 (2098--9424)641 (186--1197)4661 (1785--7975)443 (120--789)10 317 (3924--16 607)1085 (307--1881)Discontinued breastfeeding411 (43--934)89 (9--198)384 (36--857)78 (8--166)795 (82--1701)167 (17--366)Childhood underweight3495 (2229--5095)169 (106--243)3005 (1967--4351)126 (74--188)6500 (4307--9377)295 (194--426)Iron deficiency1254 (848--1817)901 (603--1297)2950 (2013--4287)1709 (1084--2565)4204 (2869--6062)2609 (1712--3861)Vitamin A deficiency336 (113--769)27 (12--47)305 (102--642)23 (10--41)641 (255--1259)49 (23--85)Zinc deficiency734 (120--1703)93 (32--184)668 (137--1442)76 (30--140)1402 (271--2935)169 (64--322)Tobacco smoking17 871 (13 586--23 735)22 710 (17 091--28 270)10 451 (7269--15 690)7295 (4467--9735)28 322 (22 504--35 727)30 005 (23 431--35 918)Tobacco smoking, excluding second-hand smoke13 956 (9733--19 432)21 193 (15 459--26 815)6228 (3208--11 636)5061 (2197--7504)20 184 (14 644--28 362)26 254 (19 643--32 224)Second-hand smoke3916 (2649--5219)1517 (1068--1967)4222 (3122--5373)2234 (1562--2979)8138 (6067--10 360)3751 (2665--4873)Alcohol and drug use11 659 (9477--14 051)13 438 (10 801--16 389)3681 (2558--4892)3183 (2223--4358)15 340 (12 458--18 572)16 621 (13 436--20 283)Alcohol use10 232 (8216--12 384)11 617 (9192--14 277)2791 (1811--3917)2163 (1247--3104)13 023 (10 502--15 741)13 780 (10 890--16 881)Drug use1459 (905--2141)1841 (1198--2784)902 (564--1338)1024 (660--1573)2360 (1615--3263)2865 (1985--4021)Physiological risksHigh fasting plasma glucose5143 (3695--6681)9199 (6530--12 137)4534 (3410--5837)6903 (5247--8653)9677 (7570--11 979)16 103 (12 903--19 824)High total cholesterol1109 (576--1785)3356 (1496--5266)1128 (661--1718)2555 (1256--3873)2237 (1437--3265)5912 (3603--8473)High blood pressure13 553 (11 374--16 218)23 326 (19 489--27 142)12 488 (10 500--15 025)14 614 (12 167--16 954)26 041 (22 752--30 040)37 940 (33 309--42 707)High body-mass index2323 (1349--3368)6852 (4719--9263)2480 (1547--3527)5404 (3570--7315)4803 (2984--6833)12 256 (8625--16 166)Low bone mineral density437 (338--567)761 (553--957)350 (268--446)474 (363--611)787 (642--965)1234 (973--1523)Dietary risks21 170 (18 259--24 481)32 913 (28 434--36 538)16 113 (13 900--19 320)18 787 (16 314--20 922)37 283 (32 882--42 124)51 700 (46 070--56 650)Diet low in fruits12 401 (9336--15 668)19 203 (14 551--23 129)9136 (6809--11 954)10 275 (7812--12 510)21 537 (16 764--26 123)29 478 (23 464--34 689)Diet low in vegetables2709 (1274--4411)3734 (1901--5848)1692 (719--2947)1529 (682--2550)4401 (2115--6869)5263 (2678--8079)Diet low in whole grains3951 (3070--4998)6591 (5157--8019)3216 (2490--4123)3989 (3126--4851)7167 (5633--8853)10 580 (8394--12 742)Diet low in nuts and seeds2508 (1619--3540)4907 (3093--6366)1971 (1252--2911)2745 (1704--3648)4479 (2906--6150)7652 (4971--9943)Diet low in milk241 (74--404)350 (105--606)192 (59--324)263 (71--461)433 (132--718)613 (176--1055)Diet high in red meat150 (71--247)297 (132--484)118 (53--197)225 (96--376)268 (126--439)522 (237--855)Diet high in processed meat289 (106--501)517 (184--883)264 (102--450)386 (162--617)553 (224--916)903 (356--1444)Diet high in sugar-sweetened beverages605 (22--1487)186 (24--1236)376 (17--1258)192 (20--1040)981 (46--2549)378 (47--1820)Diet low in fibre1472 (727--2256)2762 (1307--4167)1111 (535--1689)1532 (732--2315)2582 (1261--3910)4294 (2036--6510)Diet low in calcium332 (244--413)470 (347--675)258 (173--335)344 (242--482)590 (438--732)814 (603--1118)Diet low in seafood omega-3 fatty acids1222 (862--1759)2456 (1692--3134)941 (665--1436)1288 (868--1679)2163 (1522--3042)3745 (2633--4789)Diet low in polyunsaturated fatty acids492 (232--778)751 (331--1179)368 (166--610)398 (190--638)860 (405--1332)1150 (516--1806)Diet high in *trans* fatty acids239 (159--342)595 (378--814)190 (124--284)339 (221--465)430 (301--594)934 (632--1252)Diet high in sodium6978 (4571--9388)10 897 (7367--14 469)5142 (3311--7122)5934 (3838--7956)12 120 (7899--15 991)16 831 (11 210--21 998)Physical inactivity and low physical activity..6341 (5091--7744)..5098 (4212--6050)..11 439 (9492--13 679)Occupational risks9750 (7143--12 888)8775 (6511--11 597)3732 (2599--5023)3620 (2479--4987)13 482 (10 005--17 268)12 395 (9234--16 106)Occupational carcinogens396 (241--659)803 (420--1220)174 (102--300)286 (152--450)570 (354--907)1089 (626--1627)Occupational exposure to asbestos1 (0--10)1 (0--11)10 (0--29)6 (0--25)11 (0--31)7 (0--28)Occupational exposure to arsenic13 (5--26)26 (9--48)8 (3--17)13 (5--24)22 (8--42)38 (15--70)Occupational exposure to benzene8 (3--15)14 (6--25)9 (3--18)13 (4--26)17 (7--31)27 (11--50)Occupational exposure to beryllium1 (0--1)2 (1--3)0 (0--1)1 (0--2)1 (0--2)2 (1--4)Occupational exposure to cadmium2 (1--4)6 (2--9)1 (1--2)2 (1--4)3 (2--6)8 (4--13)Occupational exposure to chromium7 (4--12)18 (9--27)5 (3--9)10 (5--15)12 (7--19)28 (17--41)Occupational exposure to diesel engine exhaust121 (69--206)235 (115--362)32 (18--58)49 (24--77)153 (89--248)284 (150--428)Occupational exposure to second-hand smoke98 (68--157)190 (108--259)55 (37--95)97 (51--138)153 (110--227)287 (191--382)Occupational exposure to formaldehyde5 (2--11)9 (3--18)4 (2--8)5 (2--10)10 (4--18)14 (6--27)Occupational exposure to nickel38 (10--84)88 (22--183)25 (6--55)48 (13--101)63 (17--136)136 (36--279)Occupational exposure to polycyclic aromatic hydrocarbons16 (8--30)41 (18--67)8 (4--15)16 (7--28)24 (11--42)57 (27--94)Occupational exposure to silica92 (62--151)196 (109--275)21 (14--37)34 (18--50)113 (78--177)231 (138--319)Occupational exposure to sulphuric acid8 (2--20)12 (3--30)1 (0--2)1 (0--2)8 (2--21)13 (4--31)Occupational asthmagens111 (46--188)82 (45--128)70 (25--130)54 (26--93)181 (100--285)137 (83--208)Occupational particulate matter, gases, and fumes2470 (1172--3735)1578 (759--2405)1041 (487--1640)503 (227--848)3511 (1679--5286)2080 (966--3203)Occupational noise472 (263--767)488 (280--804)252 (138--421)247 (141--415)725 (410--1164)735 (428--1216)Occupational risk factors for injuries3516 (1938--6185)2538 (1435--4599)253 (94--549)145 (39--327)3769 (2135--6505)2682 (1562--4745)Occupational low back pain2786 (1707--4148)3286 (2016--4876)1941 (1115--3057)2386 (1414--3643)4727 (3007--6897)5672 (3615--8227)Sexual abuse and violence..422 (285--610)..2835 (1800--4146)..3258 (2175--4620)Childhood sexual abuse..422 (285--610)..463 (303--672)..885 (617--1232)Intimate partner violence\...\...2485 (1479--3768)..2485 (1479--3768)[^6]

Discussion {#cesec110}
==========

Between 1990 and 2010, the health profile of China changed rapidly. Premature mortality in children declined by almost 80%. The contribution of communicable, maternal, neonatal, and nutritional disorders to DALYs declined for all ages from nearly 27% in 1990 to about 10% in 2010. The burden of disease is now dominated by cardiovascular diseases, lung cancer, chronic obstructive pulmonary disease, road injuries, and key causes of chronic disabilities such as mental and musculoskeletal disorders. Although the burden of suicide, drowning, and many injuries declined, the burden of road injuries and falls is increasing. The rise of non-communicable diseases and chronic disability is fuelled by a shift away from risks for communicable diseases in children toward those for non-communicable diseases in adults. The one child policy in China implies the demographic shifts contributing to this rapid transition in health problems will intensify in the coming decades.

China has had remarkable success in decreasing death rates and disability from communicable diseases. Deaths from diarrhoea and lower respiratory infections in children younger than 5 years declined by 90% in the two decades from 1990. DALYs caused by tuberculosis dropped by about 71%. We also noted large declines for incidence of infection with intestinal nematodes, meningitis, tetanus, measles, and diarrhoea. The speed of some of these declines provides a model for other developing countries. Communicable disease-control challenges, however, are not over. The burden of HIV increased between 1990 and 2010 ([table 2](#tbl2){ref-type="table"}). 213 000 (95% UI 179 600--260 700) children younger than 5 years died in 2010, almost 60% of them from communicable, neonatal, and nutritional causes. Subnational assessments would probably reveal that the burden of communicable diseases is high in some poor provinces. China faces challenges dealing with the ongoing risk of pandemic influenza. The 2013 outbreak of H7N9 shows how the interaction between animal and human populations continues to lead to new epidemics. Through the internet-based surveillance system run by the Chinese CDC, early detection of the first human cases of H7N9 led to a coherent response. Despite progress, continued attention to the unfinished agenda for communicable disease control is required and ongoing epidemic surveillance and response is a necessity.

The burden of diseases attributable to individual behaviours and practices is steadily rising. The most important behaviours included diets low in fruit, high in sodium and low in whole grains, smoking, alcohol, and physical inactivity. Smoking prevalence in China for men is 52·9% (one of the highest rates in the world) and for women is 2·4% (one of the lowest),[@bib55] and second-hand smoke exposure is as high as 72·4%.[@bib23], [@bib56] The fraction of deaths attributable to tobacco increased from 12·8% (9·9--16·9) in 1990 to 16·4% (12·8--19·9) in 2010 ([appendix p 10](#sec1){ref-type="sec"}) and will increase because of the lag between consumption and death rates. The aggregation of 14 components of diet was the leading risk factor for DALYs in China, including the consumption of sodium and inadequate intake of fruit, whole grains, and nuts and seeds. Reliable data from the national nutrition surveys show that even rural Chinese diets dominated by rice are low in fruit, high in sodium, low in whole grains, and low in nuts and seeds. Rising incomes and a larger fraction of the population living to older ages mean that the burden attributable to these behaviours will increase. The extraordinary pace of urbanisation in China might exacerbate this transformation. The urban population in China has more than tripled in the past 30 years and the rate of urbanisation is accelerating.[@bib57], [@bib58] Although urbanisation offers opportunities for improvements in population health in China (such as access to improved health care and basic infrastructure), it also can lead to substantial health risks including ambient air pollution, occupational and traffic hazards, and poor diet and little physical activity. Associated social and economic challenges will accompany these shifts. For example, the ratio of the population older than 65 years to the working-aged population (aged 20--64 years) was 0·127 in 2010 and is expected to rise to 0·184 in 2020 and 0·26 in 2030.[@bib2]

The physical environment is an important driver of health in China. High levels of PM2·5, particularly in eastern China, have made ambient air pollution the fourth leading risk factor for DALYs.[@bib59] Use of solid fuels---in particular coal in inadequately ventilated homes---also contributes to excess mortality.[@bib59] Policies to change the physical layout of the road system and vehicle safety equipment might need to be enacted to restrict the burden of road injuries.[@bib59] Physical activity might also be influenced by urban layout. Actions to address the physical environment, however, are far beyond the scope of the National Health and Family Planning Commission. Addressing these new and substantial risks to Chinese health will require multisectorial action at national, provincial, and local levels. Such action will need careful documentation of the health harms at a local level and the potential for affordable alternative policies to reduce these harms.

Rapid reductions in fertility and age-specific mortality rates have led to many more Chinese individuals living to an old age, when rates of chronic disability are high. Incidence of health loss and health-care costs from mental disorders, musculoskeletal disorders, neurological disorders, and vision and hearing loss will steadily rise. China needs to plan for how the health system can prevent and manage these disorders cost-effectively. Along with Japan, South Korea, and Mexico, China seems to benefit from lower rates of major depression, anxiety disorders, and low back pain than do other members of the G20. This finding, however, has been challenged; true rates might be higher.[@bib36] Our findings on these rates are based on the careful assessment of all the available evidence; resolution will require more in-depth research on the potential for reporting biases in China and other countries in east Asia. The rise of chronic disability also has implications for the types of health workers China will need in the next 10--20 years; disciplines such as psychiatry, rheumatology, rehabilitation medicine, audiology, and ophthalmology might need increased investment. The recent adoption of China\'s first mental health law is a positive development in this area. The key obstacle China confronts in strengthening its public health and primary health care is a shortage of human resources. Although the Chinese Government has identified the training of family doctors as a top priority[@bib60] (and plans to train 300 000 of them in the next 10 years), these targets seem challenging to reach. Retention of qualified health professionals in rural areas, especially in poor regions, has been difficult.

Compared with many countries, China is relatively unique in having five cancers in the top 15 causes of premature mortality (Mexico, for example, has none): lung, liver, stomach, oesophageal, and colorectal. Of these cancers, the burden of lung, liver, and colorectal cancers increased between 1990 and 2010. China also has worse than G20 average rates for these cancers and oesophageal cancer. What are the policy options for China to address this unusually high burden of selected cancers? Tobacco and diet can account for important shares of stomach, colorectal, and lung cancers. Aggressive tobacco control and national efforts to encourage changes in diet will be important. Hepatitis B is related to 54·2% (95% UI 49·5--58·8) of the increasing burden of liver cancer; immunisation programmes will lead eventually to reductions but, because the median age of liver cancer burden is 55 years, several decades will need to pass before the effect of vaccination can substantially reduce the burden of this cancer. Benefits from screening and treatment for colorectal cancer[@bib61] should be assessed as to whether they are cost effective for China. Access to improved screening and treatment might also lead to improved outcomes for other cancers such as breast and cervical cancers.

Stroke and ischaemic heart disease accounted for 15·2% (13·3--16·6) of DALYs in 2010. DALY rates from stroke are nearly twice as high as ischaemic heart disease. Age-standardised rates for ischaemic heart disease increased between 1990 and 2010, although stroke rates in China were relatively constant. Increased blood pressure is the second leading risk factor in China ahead of tobacco consumption. Increased fasting plasma glucose and total cholesterol are also important risks of DALYs. Public health programmes to reduce tobacco consumption, sodium intake, and change other dietary risks are clearly important strategies for tackling of cardiovascular diseases in China. Primary care can also be a platform for delivery of interventions such as the detection and pharmacological management of raised blood pressure and cholesterol, and screening and management of diabetes, and impaired glucose tolerance. Because of China\'s hospital-centred health system, strengthening primary care to handle these and other problems will require a shift in policy focus. The massive declines in rates of death from ischaemic heart disease in many high-income countries have also been attributable to improved management of acute cardiac events and post-event care.[@bib62], [@bib63], [@bib64], [@bib65], [@bib66] China increasingly needs to provide access to high-quality medical services in communities with rising rates of cardiovascular diseases.

The Chinese Government needs to take responsibility for expansion of prevention strategies for behavioural risks; even small reductions in these risks could generate substantial health benefits. Subsidies, taxation, regulation, and information campaigns need to be prioritised to reduce tobacco use and exposure to second-hand smoke, increase consumption of fruits, whole grain, nuts, and seeds, reduce salt intake, increase physical activity, and reduce alcohol consumption. Effective policies will need to be multisectorial, engaging other sectors such as employment, income maintenance, social welfare, housing, education, and the mass media. To engender multisectorial action, the Chinese Government needs to define the goals and indicators for health development, monitor key health risk factors, select intervention strategies, and track policy implementation at a national level. This strategy will not only improve the levels of health status of the population, but contribute to sustainable development of the Chinese economy and society.

This analysis of the burden of disease in China has several important limitations. The results have the same limitations as GBD 2010.[@bib1], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29] In GBD 2010, no data existed for some of the 1160 disabling sequelae for some or even many of the countries. Results have been informed by several data sources available for China but for some disorders the data are weak or absent (eg, autism, cannabis dependence, endometriosis, and genital prolapse). In other cases, substantial differences exist between the available data sources (eg, for some cancers the cause of death data and population-based cancer registry data are inconsistent in some age groups). The reporting of UIs provides the reader with some information on the extent of the information available for China. Uncertainty could, for various reasons such as unrecognised bias in published studies, still be underestimated. The analysis of risk factors has focused on proximal and behavioural risks. The important role of social determinants[@bib67] was not quantified in the GBD 2010 because of a dearth of available data and sufficient evidence. The assessment of YLDs depends crucially on the validity of the disability weights measured by Salomon and colleagues.[@bib27] Although investigation across several countries reported no evidence of systematic differences; disability weights obtained in a national survey in China could be different from other countries.[@bib68], [@bib69] Most importantly, a national analysis for a country as large and diverse as China could mask substantial variations in key outcomes. For example, the HIV epidemic is very concentrated in some provinces.[@bib70], [@bib71] The rapid transition towards non-communicable diseases and disability is probably more advanced in eastern provinces. In view of improvements in some data systems in the previous decade, the possibility of bias exists in the measurement of some diseases overtime. We believe that the substantial efforts to correct for these biases that are part of the GBD method minimises this possibility.

In view of the pace of health change in China, the burden of diseases, injuries, and risk factors should be monitored every year. Annual assessments along with subnational detail at the provincial level ought to be undertaken. Key developments in the health information system that are underway will facilitate such an analysis. Development of a complete national vital events registration system with certification of cause of death would strikingly aid in this endeavour. In the previous 2 years alone, a rapid expansion has occurred in coverage of cause of death certification so that more than half of all deaths were captured in 2012. The national internet case reporting system can provide local level detail on 39 diseases since 2004. Several national surveys are underway or planned with large sample sizes. Ensuring that the various surveillance systems and topic-specific national surveys ultimately combine to provide a coherent picture of the prevalence of major diseases, injuries, and risk factors at the provincial level will also reduce the role of statistical estimation in generating burden of disease results. Robust annual assessments of the burden will provide China with a powerful method to benchmark progress against developed and other rapidly developing nations and assess where investments and policy action have been effective. Setting priorities for the health system, however, will also need information on the costs and consequences of different policy options, a better understanding of health inequalities and the capacity of the health system to implement change that is both efficient and fair.
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[^1]: Joint first authors

[^2]: Data in parentheses are 95% uncertainty intervals. Countries have been ranked such that the best performer is ranked 1 for each indicator. YLL=years of life lost. YLD=years lived with disability. LE=life expectancy. HALE=healthy life expectancy at birth.

[^3]: Data are deaths (95% UI) or % change. 95% UIs are shown in parentheses. Percentage change is computed for 1000 draws of each quantity in 1990 and 2010 and median percentage change is reported. UI=uncertainty interval. DALYs=disability-adjusted life-years. %Δ=percentage change. *E coli*=*Escherichia coli. H influenzae*=*Haemophilus influenzae*.

[^4]: Data in parentheses are 95% uncertainty intervals. Cause groups are ordered by the number of deaths in 2010. %Δ=percentage change.

[^5]: Data are DALYs (95% UI) or % change. UI=uncertainty interval. DALYs=disability-adjusted life-years. %Δ=percentage change. *E coli*=*Escherichia coli. H influenza*=*Haemophilus influenza*.

[^6]: 0 suggests no deaths or DALYs were attributable to risk factors or risk factor clusters. ..=attributable deaths or DALYs not quantified.
